var title_f14_0_14336="Chondroblastoma extension";
var content_f14_0_14336=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chondroblastoma with epiphyseal and metaphyseal extension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 278px; height: 443px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anterpostero plain radiograph of the knee. Observe the large chondroblastoma affecting the tibial epiphysis, with extension into the metaphysis. Observe the sharp zone of transition and clearly defined margins of this lesion. Chondroblastoma and giant cell tumor are the two most common neoplasms to affect the epiphysis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_0_14336=[""].join("\n");
var outline_f14_0_14336=null;
var title_f14_0_14337="PIP extension";
var content_f14_0_14337=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Examination of finger PIP joint extension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 302px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_0_14337=[""].join("\n");
var outline_f14_0_14337=null;
var title_f14_0_14338="Patient information: Shingles (The Basics)";
var content_f14_0_14338=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15376\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/58/12192\">",
"         Shingles (herpes zoster)",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/49/10015\">",
"          Shingles (herpes zoster)",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?26/57/27538\">",
"         Patient information: Chickenpox (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/48/12035\">",
"         Patient information: Vaccines (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/40/2691\">",
"         Patient information: Chickenpox prevention and treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/12/13507\">",
"         Patient information: Shingles (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Shingles (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/shingles-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H396030644\">",
"      <span class=\"h1\">",
"       What is shingles?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Shingles is a painful rash that is shaped like a band or a belt. Shingles can affect people of all ages, but it is most common in those older than 50. Another name for shingles is &ldquo;herpes zoster.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14657313\">",
"      <span class=\"h1\">",
"       What causes shingles?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Shingles is caused by the same virus that causes chickenpox. After someone has chickenpox, the virus sometimes hides out, &ldquo;asleep&rdquo; in the body. Years later, it can &ldquo;wake up&rdquo; and cause shingles. The first time a person is infected with that virus, he or she gets chickenpox, not shingles.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H396030651\">",
"      <span class=\"h1\">",
"       Is shingles contagious?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes and no. It is NOT possible to &ldquo;catch&rdquo; shingles from someone who has the rash. But it is possible to &ldquo;catch&rdquo; the virus and then get sick with chickenpox. Shingles and chickenpox are caused by the same virus.",
"     </p>",
"     <p>",
"      You probably will NOT catch the virus (or get chickenpox) if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Had chickenpox or shingles in the past",
"       </li>",
"       <li>",
"        Had the chickenpox vaccine",
"       </li>",
"       <li>",
"        Were born before 1980 (most people born before 1980 have had chickenpox even if they don&rsquo;t remember it)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have never had chickenpox or the chickenpox vaccine, be careful around anyone with shingles. Do not touch their rash. If you do, you could get sick with chickenpox. In rare cases, people can even get chickenpox from just being near someone with shingles. This is most likely in people who cannot fight infections well.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H396030658\">",
"      <span class=\"h1\">",
"       What are the symptoms of shingles?",
"      </span>",
"      &nbsp;&mdash;&nbsp;At first, shingles causes weird sensations on your skin. You might feel itching, burning, pain or tingling. &nbsp;Some people get a fever, feel sick, or get a headache. Within 1 to 2 days, a rash with blisters appears. Blisters most often appear in a band across the chest and back (",
"      <a class=\"graphic graphic_picture graphicRef50627 \" href=\"UTD.htm?11/58/12192\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef66249 \" href=\"UTD.htm?9/49/10015\">",
"       picture 2",
"      </a>",
"      ). They can show up on other parts of the body, too. The blisters cause pain that can be mild or severe.",
"     </p>",
"     <p>",
"      Within 3 to 4 days, shingles blisters can become open sores or \"ulcers\". These ulcers can get infected. Within 7 to 10 days, the rash should scab over. By then, most people are no longer contagious.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H396030665\">",
"      <span class=\"h1\">",
"       Can shingles be serious?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Shingles can be serious, but that is rare. About 1 out of 10 people with shingles will get something called &ldquo;postherpetic neuralgia,&rdquo; or &ldquo;PHN.&rdquo; People with PHN keep feeling pain or discomfort even after their rash goes away. This pain can last for months or even years. It can be so bad that it makes it hard to sleep, causes weight loss, and leads to depression.",
"     </p>",
"     <p>",
"      Shingles can also cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Skin infections",
"       </li>",
"       <li>",
"        Eye problems (if the rash is near the eye)",
"       </li>",
"       <li>",
"        Ear problems (if the rash is near the ear)",
"       </li>",
"       <li>",
"        Dangerous infections in people who have other health problems",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H396030672\">",
"      <span class=\"h1\">",
"       Should I be treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you see your doctor or nurse within 3 days of when your symptoms start, yes. He or she should give you medicines to help you get rid of the virus. These medicines are called anti-virals. They can speed your recovery and reduce the chances that you will have shingles-related problems such as PHN.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H396030679\">",
"      <span class=\"h1\">",
"       Can the pain be treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people can deal with their pain with non-prescription pain medicines, but most people need prescription medicines.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H396030686\">",
"      <span class=\"h1\">",
"       How should I take care of the rash?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Keep the parts of your skin that have a rash clean and dry. Do not use creams or gels unless your doctor or nurse says you should.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H396030693\">",
"      <span class=\"h1\">",
"       Can shingles be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People can reduce the chances of getting shingles by having the shingles vaccine. The vaccine can also make the symptoms of shingles milder if they do occur. Most people age 60 and older should get the shingles vaccine.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H396030700\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/57/27538?source=see_link\">",
"       Patient information: Chickenpox (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=see_link\">",
"       Patient information: Vaccines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/12/13507?source=see_link\">",
"       Patient information: Shingles (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/40/2691?source=see_link\">",
"       Patient information: Chickenpox prevention and treatment (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?14/0/14338?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15376 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.248.109.99-A662985E8F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_0_14338=[""].join("\n");
var outline_f14_0_14338=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H396030644\">",
"      What is shingles?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14657313\">",
"      What causes shingles?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H396030651\">",
"      Is shingles contagious?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H396030658\">",
"      What are the symptoms of shingles?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H396030665\">",
"      Can shingles be serious?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H396030672\">",
"      Should I be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H396030679\">",
"      Can the pain be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H396030686\">",
"      How should I take care of the rash?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H396030693\">",
"      Can shingles be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H396030700\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15376\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/58/12192\">",
"      Shingles (herpes zoster)",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/49/10015\">",
"       Shingles (herpes zoster)",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/57/27538?source=related_link\">",
"      Patient information: Chickenpox (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/40/2691?source=related_link\">",
"      Patient information: Chickenpox prevention and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/12/13507?source=related_link\">",
"      Patient information: Shingles (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=related_link\">",
"      Patient information: Vaccines (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_0_14339="Wt height boys z 2 5";
var content_f14_0_14339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 627px\">",
"   <div class=\"ttl\">",
"    Weight-for-height boys: 2 to 5 years (z-scores)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 607px; height: 388px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The WHO Child Growth Standards. World Health Organization, Geneva, 2008. Available at file://www.who.int/childgrowth/standards/en/. Copyright &copy;2008 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_0_14339=[""].join("\n");
var outline_f14_0_14339=null;
var title_f14_0_14340="Diatrizoate meglumine: Drug information";
var content_f14_0_14340=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diatrizoate meglumine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/48/42755?source=see_link\">",
"    see \"Diatrizoate meglumine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F158941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cystografin&reg;;",
"     </li>",
"     <li>",
"      Cystografin&reg; Dilute",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F158943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Iodinated Contrast Media;",
"     </li>",
"     <li>",
"      Radiological/Contrast Media (Ionic, High Osmolality)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5283842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosing is based upon route of administration, type of examination, age of patient, and product used. Consult specific product information for detailed dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F5284179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15796034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15796035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F158933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for instillation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cystografin&reg;: 30% (100 mL, 300 mL) [contains edetate disodium; provides organically-bound iodine ~141 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cystografin&reg; Dilute: 18% (300 mL) [contains edetate disodium; provides organically-bound iodine ~85 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F158930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5261786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer slower in the elderly and heart failure patients. Slow infusion if nausea or flushing occurs. For intravenous use, should be at body temperature for administration. In angiography, use meticulous intravascular administration technique to minimize thrombotic events including frequent catheter flushing, and close attention to catheter and guidewire manipulation.",
"     <b>",
"      Note:",
"     </b>",
"     Some products (eg, Cystografin&reg;, Reno-30&reg;) are intended only for instillation and are not to be administered I.V.; consult product labeling to avoid inadvertent erroneous administration.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F158934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution for instillation: Retrograde cystourethrography; retrograde or ascending pyelography",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution for injection: Arthrography, cerebral angiography, direct cholangiography, discography, drip infusion pyelography, excretory urography, peripheral arteriography, splenoportography, venography; contrast enhancement of computed tomographic head and body imaging",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5261780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Flushing (49%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Taste perversion (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site reaction (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Nephrosis (excretory urography: 23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Edema, hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (5%), agitation, chills, fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Urticaria (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (6%), vomiting (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Extravasation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Parasthesia (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Hematuria (retrograde GU procedures), urinary tract infections (retrograde GU procedures)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (2%), rhinitis (1%), sneezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Allergic reaction, diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactic shock, anemia, angioneurotic edema, anuria, apnea, asthma, bradycardia (sinus), bronchospasm, BUN increased, cardiac arrest, cardiorespiratory failure, chest pain, coma, confusion, conjunctival irritation, creatinine increased, cyanosis, dyspnea, fibrillation (ventricular), gangrene (extremities), hematoma (cerebral), hypotension, itching eyes, lacrimation, laryngeal edema, leukopenia, neutropenia, oliguria, pain, paresis, parotid glands swelling, petechiae, pruritus, pulmonary edema, pulmonary embolism, rash, renal colic (retrograde GU procedures), renal failure, respiratory arrest, seizure, shock (urography), speech disorder, syncope, tachycardia (reflex), thrombocytopenia, thrombophlebitis, uremia, urinary tract spasm (retrograde GU procedures), ventricular fibrillation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F158936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to diatrizoate or any component of the formulation; solutions for instillation should not be used for intravascular injection; solutions for injection are not for intrathecal use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Refer to product labeling for procedure-specific contraindications.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5261520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Allergic reactions: Use extreme caution with history of previous reaction to contrast dye or iodine-based contrast media. Severe, potentially life-threatening, reactions and delayed reactions may occur. Monitor closely after injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Extravasation: Use meticulous intravascular administration technique.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Heart failure: Use caution in heart failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic disease: Use caution in severe hepatic failure. Avoid diagnostic infusion studies in patients with hepatic or biliary disease who have recently taken cholecystographic contrast agent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypertension: Use caution in hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperthyroidism: Use caution; thyroid storm following use of intravascular iodinated contrast agents has been rarely reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Multiple myeloma: Use caution in multiple myeloma; use of intravascular contrast agents may lead to renal dysfunction, especially with concurrent dehydration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pheochromocytoma: Use extreme caution in pheochromocytoma; monitor blood pressure closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal disease: Use caution in renal disease. May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in diabetics, the elderly, and those who are dehydrated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sickle cell disease: May exacerbate sickle cell disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Subarachnoid hemorrhage: Use caution in subarachnoid hemorrhage; reports of clinical deterioration have occurred with administration of contrast media.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thromboembolism: Serious, rarely fatal, thromboembolic events causing myocardial infarction (MI) and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Ionic iodinated contrast media may inhibit blood coagulation. Use meticulous intravascular administration techniques during angiographic procedures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Instillation: Some products (eg, Cystografin&reg;, Reno-30&reg;) are intended only for instillation and are not to be administered I.V.; consult product labeling to avoid inadvertent erroneous administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate administration:",
"     <b>",
"      [U.S. Boxed Warning]:",
"     </b>",
"     Injectable solution should never be used intrathecally.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6219792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: Iodinated Contrast Agents may enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis.  Management: Withhold metformin from all patients receiving intravascular iodinated contrast agents prior to or at the time of the procedure and for at least 48 hrs thereafter.  Document adequate renal function before restarting metformin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F158931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F158938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Diatrizoate salts cross the placenta and may enter fetal circulation. Abnormal neonatal opacification of the small intestine and colon have been reported in the newborn 4-6 days after delivery. In general, iodinated contrast media agents are avoided during pregnancy unless essential for diagnosis.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F158942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F158939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diatrizoate salts are reported to be excreted in human milk",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9730006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cystografin Urethral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30% (100 mL): $35.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cystografin-Dilute Urethral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     18% (300 mL): $36.99",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Committee on Obstetric Practice, &ldquo;ACOG Committee Opinion. Guidelines for Diagnostic Imaging During Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2004, 104(3):647-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/0/14340/abstract-text/15339791/pubmed\" id=\"15339791\" target=\"_blank\">",
"        15339791",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8454 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-294E67EF58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_0_14340=[""].join("\n");
var outline_f14_0_14340=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708698\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158941\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158943\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5283842\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5284179\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796034\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796035\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158933\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158930\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5261786\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158934\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174522\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5261780\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158936\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5261520\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299175\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6219792\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158931\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158938\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158942\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158939\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9730006\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323105\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8454\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8454|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/48/42755?source=related_link\">",
"      Diatrizoate meglumine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_0_14341="Clioquinol and flumethasone: Patient drug information";
var content_f14_0_14341=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Clioquinol and flumethasone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/13/29907?source=see_link\">",
"     see \"Clioquinol and flumethasone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F183762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Locacorten&reg; Vioform&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691827",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat ear infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701828",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to clioquinol, flumethasone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705375",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Ear:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701377",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a ruptured ear drum.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697666",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may stain fingernails, hair, and skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect clothing and fabrics from staining.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired, weak, or touchy; trembling; having a fast heartbeat, confusion, sweating, or dizziness if you missed a dose or recently stopped this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699026",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad ear pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695110",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If using on the groin, use a little bit. Do not wear tight clothing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705375",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Ear:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the ear only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lie on your side with problem ear up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pull the outer ear outward and upward.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695239",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put drops in ear without touching dropper to ear. Stay on side for 2 minutes or put cotton plug in ear.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11934 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-CCB85E928E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_0_14341=[""].join("\n");
var outline_f14_0_14341=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183762\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028767\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028766\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028771\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028772\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028774\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028769\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028770\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028775\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028776\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/13/29907?source=related_link\">",
"      Clioquinol and flumethasone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_0_14342="Rumination syndrome manometry";
var content_f14_0_14342=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Esophageal pH measurement and gastroduodenal manometry in rumination syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Measurement of esophageal pH and gastroduodenal manometry in a patient with rumination syndrome reveal simultaneous drops in intraesophageal pH and increases in intraabdominal pressure at the time the patient experiences regurgitation (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Camilleri, M, Prather, CM, In: Sleisenger and Fordtran's Gastrointestinal Disease, 6th ed, Feldman, M, Scharschmidt, BF, Sleisenger, MH (Eds). WB Saunders, Philadelphia 1998. p.572.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_0_14342=[""].join("\n");
var outline_f14_0_14342=null;
var title_f14_0_14343="Measles, mumps, and rubella vaccines (combined): Drug information";
var content_f14_0_14343=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Measles, mumps, and rubella vaccines (combined): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/41/658?source=see_link\">",
"    see \"Measles, mumps, and rubella vaccines (combined): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12215?source=see_link\">",
"    see \"Measles, mumps, and rubella vaccines (combined): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F191454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      M-M-R&reg; II",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F191455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      M-M-R&reg; II;",
"     </li>",
"     <li>",
"      Priorix&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F191466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vaccine, Live (Viral)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3012839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Immunization:",
"     </b>",
"     SubQ: 0.5 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Birth year in or after 1957 without evidence of immunity: 1 or 2 doses (0.5 mL/dose); minimum interval between doses is 28 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults born in or after 1957 without documentation of live vaccine on or after first birthday, or without physician-diagnosed measles or mumps, or without laboratory evidence of immunity, should be vaccinated with at least one dose; a second dose, separated by no less than 1 month, is indicated for those previously vaccinated with one dose of measles vaccine, students entering institutions of higher learning, recently exposed in an outbreak setting, healthcare workers at time of employment, and for travelers to endemic areas (CDC, 1998).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Persons vaccinated between 1963 and 1967 with a killed measles vaccine, followed by live vaccine within 3 months, or with a vaccine of unknown type should be revaccinated with live measles virus vaccine. Persons vaccinated before 1979 with either a killed mumps vaccine or a mumps vaccine of unknown type should be considered for revaccination with two doses of MMR (CDC, 1998).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Women of childbearing potential, without documentation of rubella immunity, regardless of birth year, should also receive one dose of vaccine. Do not administer rubella to women who are or who may become pregnant within 1 month of receiving vaccine; administer following completion or termination of pregnancy (CDC, 1998).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Healthcare personnel (unvaccinated) born prior to 1957 and who are without laboratory evidence of measles, mumps, and/or rubella immunity or laboratory confirmation of disease:  Consider 2 doses of MMR vaccine at the appropriate interval. Two doses of the MMR vaccine are needed for measles and mumps, one dose is needed for rubella (CDC, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F191461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12215?source=see_link\">",
"      see \"Measles, mumps, and rubella vaccines (combined): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Immunization:",
"     </b>",
"     SubQ:",
"     <i>",
"      Children &ge;12 months:",
"     </i>",
"     0.5 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Primary immunization is recommended at 12-15 months of age and repeated at 4-6 years of age; the second dose is recommended prior to elementary school. If the second dose was not received, the schedule should be completed by the 11- to 12-year old visit. (The second dose may be administered at any time provided at least 4 weeks have elapsed since the first dose.)  For older children not previously vaccinated, at least 28 days should elapse between doses (CDC, 1998).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      International travel:",
"     </b>",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Infants 6-11 months:",
"     </i>",
"     Children traveling internationally should receive 1 dose of MMR before departure from the United States; these children should be revaccinated with 2 doses of MMR with the first dose between 12-15 months of age (and at least 4 weeks after the previous dose) and the second dose at least 4 weeks later (CDC, 2013a).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &ge;12 months:",
"     </i>",
"     Children traveling internationally should receive 2 doses of MMR before departure from the United States. The first dose given &ge;12 months of age and the second dose &ge;4 weeks later (CDC, 2013a).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Measles outbreak:",
"     </b>",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Infants 6-11 months:",
"     </i>",
"     If there is risk of exposure to measles, single-antigen measles vaccine should be administered. If single-antigen vaccine is not readily available, MMR is an acceptable alternative. Children should be revaccinated at &ge;12 months with standard 2-dose series (CDC, 1998).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &ge;12 months:",
"     </i>",
"     Revaccination with MMR is recommended for attendees and siblings of daycare facilities or schools if they cannot provide adequate documentation of 2 previous doses of a measles-containing vaccine after their first birthday or evidence of measles immunity (CDC, 1998).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mumps outbreak:",
"     </b>",
"     SubQ:",
"     <i>",
"      Children &ge;12 months:",
"     </i>",
"     During a mumps outbreak, children ages 1-4 years should consider a second dose of a live mumps virus vaccine; minimum interval between doses is 28 days (CDC, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16317817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16317818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F191436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     M-M-R&reg; II: Measles virus &ge;1000 TCID",
"     <sub>",
"      50",
"     </sub>",
"     , mumps virus &ge;20,000 TCID",
"     <sub>",
"      50",
"     </sub>",
"     , and rubella virus &ge;1000 TCID",
"     <sub>",
"      50",
"     </sub>",
"     [contains albumin (human), bovine serum, chicken egg protein, gelatin, neomycin, sorbitol, and sucrose 1.9 mg/vial; supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F191422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F191439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer SubQ in outer aspect of the upper arm in patients &ge;12 months.",
"     <b>",
"      Not for I.V. administration.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Simultaneous administration of vaccines helps ensure the patients will be fully vaccinated by the appropriate age. Simultaneous administration of vaccines is defined as administering &gt;1 vaccine on the same day at different anatomic sites. The use of licensed combination vaccines is generally preferred over separate injections of the equivalent components. Separate vaccines should not be combined in the same syringe unless indicated by product specific labeling. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible. Adolescents and adults should be vaccinated while seated or lying down. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F191437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Measles, mumps, and rubella prophylaxis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     &bull; All children (first dose given at 12-15 months of age)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     &bull; Adults born 1957 or later (without evidence of immunity or documentation of vaccination).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     &bull; Adults at higher risk for exposure to and transmission of measles mumps and rubella should receive special consideration for vaccination, unless an acceptable evidence of immunity exists. This includes international travelers, persons attending colleges and other post-high school education, persons working in healthcare facilities.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6266587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       MMR (measles, mumps and rubella virus vaccine) may be confused with MMRV (measles, mumps, rubella, and varicella) vaccine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F191464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Syncope, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Ataxia, dizziness, febrile seizure, fever, encephalitis, encephalopathy, Guillain-Barr&eacute; syndrome, headache, irritability, malaise, measles inclusion body encephalitis, polyneuritis, polyneuropathy, seizure, subacute sclerosing panencephalitis,",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Angioneurotic edema, erythema multiforme, measles-like rash, pruritus, purpura, rash, Stevens-Johnson syndrome, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Diabetes mellitus, parotitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, pancreatitis, sore throat, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Epididymitis, orchitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukocytosis, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions which include burning, induration, redness, stinging, swelling, tenderness, wheal and flare, vesiculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia/arthritis (variable; highest rates in women, 12% to 26% versus children, up to 3%), myalgia, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis, ocular palsies, optic neuritis, papillitis, retinitis, retrobulbar neuritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Nerve deafness, otitis media",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Conjunctivitis, retinitis, optic neuritis, papillitis, retrobulbar neuritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchospasm, cough, pneumonia, pneumonitis, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reactions, anaphylaxis, atypical measles, panniculitis, regional lymphadenopathy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F191441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to measles, mumps, and/or rubella vaccine or any component of the formulation; current febrile respiratory illness or other febrile infection; patients receiving immunosuppressive therapy (does not include corticosteroids as replacement therapy); primary and acquired immunodeficiency states; individuals with blood dyscrasias, leukemia, lymphomas, or other malignant neoplasms affecting the bone marrow or lymphatic systems; family history of congenital or hereditary immunodeficiency (until immune competence in the vaccine recipient is demonstrated); pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F191426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syncope: Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute illness: May consider deferring administration in patients with moderate or severe acute illness (with or without fever). Per the ACIP, may administer to patients with mild acute illness (with or without fever).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS disorders: Use with caution in patients with history of cerebral injury, seizures, or other conditions where stress due to fever should be avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Measles exposure: Exposure to measles is not a contraindication to vaccine; use within 72 hours of exposure may provide some protection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombocytopenia: Use with caution in patients with thrombocytopenia and those who develop thrombocytopenia after first dose; thrombocytopenia may worsen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tuberculosis: Defer vaccination in patients with active untreated tuberculosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune globulins: Recent administration of immune globulins may interfere with immune response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccines:  In order to maximize vaccination rates, the ACIP recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and potential adverse events. When using combination vaccines, the minimum age for administration is the oldest minimum age for any individual component; the minimum interval between dosing is the greatest minimum interval between any individual component.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered immunocompetence: Use is contraindicated in severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]); may have a reduced response to vaccination. Patients with HIV infection, who are asymptomatic and not severely immunosuppressed may be vaccinated. Patients with leukemia who are in remission and who have not received chemotherapy for at least 3 months may be vaccinated. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Healthcare workers: Acceptable evidence of immunity is recommended for healthcare workers at time of employment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy of measles vaccine has not been established in children &lt;6 months of age and safety and efficacy of mumps and rubella vaccines have not been established in &lt;12 months of age.  Local health departments may recommend vaccine to children 6-12 months of age in outbreak situations, but this would not count towards their immunization series.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Students: Acceptable evidence of immunity is recommended for students entering institutions of higher learning.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Travelers to endemic areas: Acceptable evidence of immunity is recommended for travelers to endemic areas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Egg allergy: Vaccine may contain trace amounts of chick embryo antigen. Use caution in patients with history of immediate hypersensitivity/anaphylactic reactions following egg ingestion. Generally, the MMR vaccine can be safely administered to persons with an egg allergy (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	Gelatin: Products may contain gelatin. Use is contraindicated in patients with a history of anaphylactic/anaphylactoid reaction to gelatin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neomycin sensitivity: Manufactured with neomycin. Use is contraindicated in patients with history of anaphylactic/anaphylactoid reactions to neomycin. Contact dermatitis due to neomycin is not a contraindication to the vaccine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood products: Recent administration of blood or blood products may interfere with immune response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F191430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Fingolimod may diminish the therapeutic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydroxychloroquine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immune Globulins: May diminish the therapeutic effect of Vaccines (Live). Management: Live organism vaccination should be withheld for up to 6 months following immune globulin administration.  Live vaccine given immediately prior to immune globulin may require repeat vaccination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     AzaTHIOprine; Beclomethasone (Oral Inhalation); Betamethasone; Budesonide (Systemic, Oral Inhalation); Corticotropin; Cortisone; Cytarabine (Liposomal); Dexamethasone (Systemic); Fludrocortisone; Fluticasone (Oral Inhalation); Hydrocortisone (Systemic); Hydroxychloroquine; Leflunomide; Mercaptopurine; Methotrexate; MethylPREDNISolone; PrednisoLONE (Systemic); PredniSONE; Triamcinolone (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tuberculin Tests: Vaccines (Live) may diminish the diagnostic effect of Tuberculin Tests.  Management: If a parenteral live vaccine has been recently administered, a scheduled PPD skin test should not be administered for at least 4-6 weeks following the administration of the vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F191433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F191445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. It is not known whether this vaccine can cause fetal harm or affect reproduction capacity. Based on information collected following inadvertent administration during pregnancy, adverse events have not been observed following use of rubella or mumps vaccines. However, theoretical risks cannot be ruled out; do not administer to pregnant females. The Advisory Committee on Immunization Practices (ACIP) recommends that pregnancy should be avoided for 1 month following vaccination. Adverse events have been reported following natural infection in unvaccinated pregnant women. Measles infection during pregnancy may increase the risk of premature labor, spontaneous abortion and low birth weights. Rubella infection during the first trimester may lead to congenital rubella syndrome (includes auditory, ophthalmic, cardiac and neurologic defects), growth retardation, bone defects, hepatosplenomegaly, thrombocytopenia and/or purpuric skin lesions; fetal rubella infection can occur during any trimester of pregnancy. Maternal mumps infection during the first trimester may increase the risk of fetal death. Women of childbearing age without documentation of rubella vaccination or serologic evidence of immunity should be vaccinated (for women of childbearing potential, birth prior to 1957 is not acceptable evidence of immunity to rubella). Women who are pregnant should be vaccinated upon completion or termination of pregnancy, prior to discharge (CDC, 1998; CDC, 2001).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F191458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Measles/mumps: Excretion in breast milk unknown/use caution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rubella: Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F191446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lactating women may secrete the rubella component of the vaccine into breast milk. Evidence of rubella infection has occurred in breast-fed infants following maternal immunization, most without severe disease. It is not known if the measles or mumps components of the vaccine are found in breast milk. The manufacturer recommends that caution be used if administered to nursing women. Breast-feeding is not a contraindication to vaccination (CDC, 1998). Breast-feeding infants should be vaccinated according to the recommended schedules (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7696763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F191447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      M-M-R II (CZ, ID, MY, NZ, TH);",
"     </li>",
"     <li>",
"      M-M-R Vax (AT, DE);",
"     </li>",
"     <li>",
"      M.M.R. Vaccine (KP);",
"     </li>",
"     <li>",
"      MMR II (AR, CH, CL, GB, HK, NO, PH, SE, TW);",
"     </li>",
"     <li>",
"      Morupar (MX, PH);",
"     </li>",
"     <li>",
"      Mumeru Vax (PH);",
"     </li>",
"     <li>",
"      Pluserix (BB, BF, BJ, BM, BS, BZ, CI, ET, GH, GM, GN, GY, JM, KE, LR, MA, ML, MR, MU, MW, NE, NG, NL, SC, SD, SL, SN, SR, TN, TT, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Priorix (AU, BB, BM, BS, BZ, GB, GY, IE, IL, JM, KP, NL, NO, PH, SE, SR, TT, TW);",
"     </li>",
"     <li>",
"      R.O.R. Vax (FR);",
"     </li>",
"     <li>",
"      Trimovax (BG, HK, IT, PK, TH, TW);",
"     </li>",
"     <li>",
"      Triviraten Berna (HK, MY, NZ, PH, TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F191425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a live, attenuated vaccine, MMR vaccine offers active immunity to disease caused by the measles, mumps, and rubella viruses.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule for Persons Aged  0 through 18 Years - United States, 2013,\"",
"      <i>",
"       MMWR Surveill Summ",
"      </i>",
"      , 2013a, 62(1):2-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/0/14343/abstract-text/23364302/pubmed\" id=\"23364302\" target=\"_blank\">",
"        23364302",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule for Adults Aged 19 Years and Older - United States, 2013,\"",
"      <i>",
"       MMWR Surveill Summ",
"      </i>",
"      , 2013b, 62(1):9-19.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/0/14343/abstract-text/23364303/pubmed\" id=\"23364303\" target=\"_blank\">",
"        23364303",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Measles, Mumps, and Rubella -- Vaccine Use and Strategies for Elimination of Measles, Rubella, and Congenital Rubella Syndrome and Control of Mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 1998, 47(RR-8):1-57. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/PDF/rr/rr4708.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/PDF/rr/rr4708.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/0/14343/abstract-text/9639369/pubmed\" id=\"9639369\" target=\"_blank\">",
"        9639369",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Immunization of Health-Care Personnel: Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(RR-7):1-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/0/14343/abstract-text/22108587/pubmed\" id=\"22108587\" target=\"_blank\">",
"        22108587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Notice to Readers: Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP) for the Control and Elimination of Mumps,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2006, 55(early release):1-2. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/pdf/wk/mm55e601.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/pdf/wk/mm55e601.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/0/14343/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Revised ACIP Recommendation for Avoiding Pregnancy After Receiving a Rubella-Containing Vaccine,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2001, 50(49):1117.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/0/14343/abstract-text/11794623/pubmed\" id=\"11794623\" target=\"_blank\">",
"        11794623",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control, &ldquo;Simultaneous Administration of Varicella Vaccine and Other Recommended Childhood Vaccine,&rdquo;",
"      <i>",
"       MMWR",
"      </i>",
"      , 2001, 50(47):1058-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/0/14343/abstract-text/11808928/pubmed\" id=\"11808928\" target=\"_blank\">",
"        11808928",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Syncope After Vaccination -- United States, January 2005-July 2007,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/0/14343/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nolan T, Bernstein DI, Block SL, et al, &ldquo;Safety and Immunogenicity of Concurrent Administration of Live Attenuated Influenza Vaccine With Measles-Mumps-Rubella and Varicella Vaccines to Infants 12 to 15 Months of Age,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(3):508-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/0/14343/abstract-text/18310199/pubmed\" id=\"18310199\" target=\"_blank\">",
"        18310199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Plichta AM, &ldquo;Immunization: Protecting Older Patients From Infectious Disease,&rdquo;",
"      <i>",
"       Geriatrics",
"      </i>",
"      , 1996, 51(9):47-52.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/0/14343/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, &ldquo;Febrile seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008,  121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/0/14343/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9591 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-4F5D24ED7D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_0_14343=[""].join("\n");
var outline_f14_0_14343=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191454\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191455\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191466\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3012839\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191461\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16317817\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16317818\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191436\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191422\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191439\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191437\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6266587\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191464\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191441\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191426\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299648\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191430\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191433\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191445\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191458\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191446\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7696763\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191447\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191425\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9591\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9591|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/41/658?source=related_link\">",
"      Measles, mumps, and rubella vaccines (combined): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12215?source=related_link\">",
"      Measles, mumps, and rubella vaccines (combined): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_0_14344="Female pattern hair loss (androgenetic alopecia in women): Treatment and prognosis";
var content_f14_0_14344=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Female pattern hair loss (androgenetic alopecia in women): Treatment and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/0/14344/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/0/14344/contributors\">",
"     Amy McMichael, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/0/14344/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/0/14344/contributors\">",
"     Maria Hordinsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/0/14344/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/0/14344/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/0/14344/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H633853598\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Female pattern hair loss (FPHL, female pattern alopecia, androgenetic alopecia in women) is a common form of nonscarring hair loss that most frequently occurs in adult women and primarily involves the frontal scalp and vertex of the scalp. Untreated, FPHL results in a slow, progressive decline in the density of scalp hair.",
"   </p>",
"   <p>",
"    Multiple therapies have been used for the management of FPHL. Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    is considered the first-line treatment. Data are limited on the efficacy of other agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     cyproterone acetate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    . Hair transplantation surgery is an option for women who have inadequate responses to medical therapy.",
"   </p>",
"   <p>",
"    The treatment and prognosis of FPHL will be reviewed here. The pathogenesis, clinical manifestations, and diagnosis of FPHL and the diagnosis and management of androgenetic alopecia in men (male pattern hair loss) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31752?source=see_link\">",
"     \"Female pattern hair loss (androgenetic alopecia in women): Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10856?source=see_link\">",
"     \"Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23336?source=see_link\">",
"     \"Treatment of androgenetic alopecia in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H633853605\">",
"    <span class=\"h1\">",
"     GENERAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of treatment, FPHL leads to progressive hair loss in affected areas, though not to complete baldness. Women may find the loss of hair distressing, and many women who present for the evaluation of FPHL desire treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31752?source=see_link&amp;anchor=H352182082#H352182082\">",
"     \"Female pattern hair loss (androgenetic alopecia in women): Pathogenesis, clinical features, and diagnosis\", section on 'Psychosocial dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As in the treatment of many other forms of hair loss, it is essential to thoroughly inform the patient of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The therapeutic options (including the side effects of treatments)",
"     </li>",
"     <li>",
"      The importance of long-term, consistent adherence to treatment",
"     </li>",
"     <li>",
"      The prolonged time usually required to achieve a clinically evident response (often several months)",
"     </li>",
"     <li>",
"      Realistic expectations for the results of treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The primary therapeutic goals in women with FPHL are to minimize further hair loss and to induce regrowth of terminal hairs. Photographs are valuable aids for following the response to treatment.",
"   </p>",
"   <p>",
"    The response to treatment varies widely. In our experience, not all women who respond to treatment achieve cosmetically significant hair regrowth. In some women, a positive response to treatment manifests only as a reduction in the progression of hair loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H633853612\">",
"    <span class=\"h1\">",
"     FIRST-LINE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the interventions utilized for FPHL, topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    has the strongest evidence in support of its efficacy. Topical minoxidil is also a relatively safe treatment. (See",
"    <a class=\"local\" href=\"#H633853647\">",
"     'Side effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H633853619\">",
"    <span class=\"h2\">",
"     Topical minoxidil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    is available in a variety of formulations. In the United States, minoxidil may be obtained as a 2% solution, 5% solution, or 5% foam.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H633853626\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact mechanism through which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    improves FPHL is not completely understood. It is theorized that the drug may prolong the anagen (growth) phase of hair follicles, shorten the telogen (resting) phase, and induce enlargement of miniaturized follicles, thereby contributing to the conversion of miniaturized hairs to terminal hairs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23336?source=see_link&amp;anchor=H956509#H956509\">",
"     \"Treatment of androgenetic alopecia in men\", section on 'Mechanism of action'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    for FPHL is supported by a systematic review and meta-analysis of randomized trials that found that women treated with topical minoxidil (1, 2, or 5% formulations) were significantly more likely to report clinically significant hair regrowth than women in the placebo groups (relative risk 1.86, 95% CI 1.42-2.43) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, the mean increase in hair counts within treated areas was higher in women treated with minoxidil than in women in the placebo groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H633853633\">",
"    <span class=\"h3\">",
"     Product selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although 2%",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    solution is well-accepted as a treatment for FPHL, the use of 5% minoxidil (the concentration used to treat male androgenetic alopecia) is more controversial. Only the 2% solution is approved by the US Food and Drug Administration for use in women.",
"   </p>",
"   <p>",
"    However, based upon limited data that suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    5% solution may be more effective than minoxidil 2% solution, many clinicians, including ourselves, often treat women with FPHL with the 5% solution or foam. A potential downside of use of the 5% solution is an increase in adverse effects, such as scalp irritation and hypertrichosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     Minoxidil",
"    </a>",
"    5% foam offers drug delivery in a vehicle that may be preferred by some women. Once daily application of minoxidil 5% foam appears to be effective for FPHL and may be less likely to induce side effects than twice daily application of the 2% solution [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Details of trials that have compared 2% and 5% concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    are provided below: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 48-week randomized trial in which 381 women with FPHL were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"       minoxidil",
"      </a>",
"      2% solution, minoxidil 5% solution, or a placebo solution twice daily found that both formulations of minoxidil were effective for improving hair loss [",
"      <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/3\">",
"       3",
"      </a>",
"      ]. The 5% solution was superior to placebo for all three primary efficacy measures (change in nonvellus hair count, patient assessment of visible change, and investigator assessment of visible change), and the 2% solution was superior to placebo in hair counts and investigator assessment. In addition, patient assessment of the benefit of treatment was significantly greater in the 5% minoxidil group than in the 2% minoxidil group.",
"      <br/>",
"      <br/>",
"      However, patients treated with 5% minoxidil were more likely to experience scalp pruritus, local irritation, and hypertrichosis during treatment than those treated with the 2% formulation. Facial hypertrichosis occurred in 3 percent of patients treated with 5% minoxidil; hypertrichosis did not occur in the other groups.",
"     </li>",
"     <li>",
"      The efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"       minoxidil",
"      </a>",
"      5% foam (applied once daily) and minoxidil 2% solution (applied twice daily) was compared in a 24-week randomized trial of 113 women with FPHL [",
"      <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/4\">",
"       4",
"      </a>",
"      ]. Although a trend towards greater improvement in hair counts, hair width, and overall efficacy based upon photographic assessments was seen in the patients treated with the 5% foam, this was not statistically significant.",
"      <br/>",
"      <br/>",
"      Of note, scalp pruritus (mild to moderate) and dandruff were less likely to occur in women treated with the 5% foam than in women treated with the 2% solution (16 versus 37 percent and 5 versus 18 percent, respectively). Hypertrichosis was more likely to occur in women treated with the 2% solution; sideburn hypertrichosis occurred in 26 versus 11 percent of women. Additionally, women treated with the 5% foam were significantly more likely to feel that the treatment did not interfere with the styling of hair.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H633853640\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be instructed to apply",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    to the scalp, not the hair. Women should apply the product at least two hours before bed to allow adequate time for drying. This may help to avoid the inadvertent spread of the solution to other body sites during sleeping.",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    takes at least four months to exhibit a visible effect. Use of the product for at least 12 months prior to concluding inefficacy is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H633853647\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shedding of hair commonly occurs during the first two to eight weeks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], an event likely due to the release of telogen hairs as follicles are stimulated to transition from telogen to the anagen phase [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients should be warned about this side effect to avoid the premature cessation of treatment.",
"   </p>",
"   <p>",
"    Potential local adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    include scalp pruritus, flaking, and facial hypertrichosis. The low risk for scalp irritation with use of the 5% foam formulation may be related to the absence of propylene glycol, a common contact allergen, in this formulation. Hypertrichosis usually resolves within four months if treatment is discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23336?source=see_link&amp;anchor=H956530#H956530\">",
"     \"Treatment of androgenetic alopecia in men\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H633853654\">",
"    <span class=\"h1\">",
"     SECOND-LINE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic agents that inhibit androgen production or action, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     cyproterone acetate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    , are primarily used for the management of FPHL in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with FPHL related to hyperandrogenism",
"     </li>",
"     <li>",
"      Women who respond poorly to monotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"       minoxidil",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although some studies and case reports suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     cyproterone acetate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    can improve FPHL, data on the efficacy of these therapies in FPHL are limited. No randomized trials have been performed, and a systematic review found insufficient evidence to confirm the efficacy of these interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Due to the absence of sufficient evidence to confirm the efficacy of these agents, some authors have suggested limiting their use to women with hyperandrogenism [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/5\">",
"     5",
"    </a>",
"    ]. However, there is some evidence that suggest that both women with hyperandrogenism and without hyperandrogenism may respond to hormonal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. We have seen favorable responses in both populations.",
"   </p>",
"   <p>",
"    In general, our first choice for systemic treatment is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    due to the extensive history of use of this drug in women for other indications (eg, hirsutism, acne, polycystic ovarian syndrome).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     Cyproterone acetate",
"    </a>",
"    is used for FPHL in many countries, but is not available in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/11\">",
"     11",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/23/4470?source=see_link\">",
"     Flutamide",
"    </a>",
"    is used infrequently for FPHL due to concerns regarding drug-induced hepatotoxicity. We typically instruct patients to continue topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    during systemic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H633853661\">",
"    <span class=\"h2\">",
"     Spironolactone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     Spironolactone",
"    </a>",
"    is an aldosterone antagonist that competitively blocks androgen receptors and weakly inhibits androgen synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Data in support of the use of spironolactone for FPHL include an open-label study, case reports, and case series [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/7,14-17\">",
"     7,14-17",
"    </a>",
"    ]. In the open-label study, 80 women (ages 12 to 79, most with normal androgen levels) were treated with spironolactone (200 mg per day) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     cyproterone acetate",
"    </a>",
"    (50 mg per day for postmenopausal women and 100 mg per day for 10 days per month in conjunction with an oral contraceptive pill for premenopausal women) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/7\">",
"     7",
"    </a>",
"    ]. All women were treated for at least 12 months, and the average duration of treatment was 16 months. No significant difference in efficacy was detected between the two treatments. Overall, 44 percent of patients had regrowth, 44 percent had no change in hair density, and 12 percent had continued hair loss.",
"   </p>",
"   <p>",
"    Although formal studies of the efficacy of combination therapy have not been performed, we usually continue treatment with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    in patients who receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    therapy. In a case report, the addition of minoxidil 5% solution (applied twice daily) appeared to augment clinical improvement in FPHL in a woman who was taking spironolactone (200 mg per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The typical dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    utilized for adult women with FPHL is 200 mg per day. Treatment is usually begun at a lower dose (eg, 50 mg per day). The daily dose may be increased by 50 mg monthly as tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/18\">",
"     18",
"    </a>",
"    ]. Spironolactone should be continued for at least six months prior to assessing its efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    include headache, decreased libido, menstrual irregularities, orthostatic hypotension, fatigue, and hyperkalemia. Spironolactone may cause feminization of a male fetus, and should not be administered during pregnancy. The drug is often given in conjunction with oral contraceptives in premenopausal women to prevent pregnancy, as well as to reduce menstrual irregularity. Serum potassium levels and blood pressure should be followed periodically [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H633865258\">",
"    <span class=\"h2\">",
"     Cyproterone acetate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     Cyproterone acetate",
"    </a>",
"    is an antiandrogen that may be effective for FPHL.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     Cyproterone",
"    </a>",
"    acetate is not available in the United States.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     cyproterone acetate",
"    </a>",
"    in FPHL is difficult to assess since studies evaluating the efficacy of the drug have used variable treatment regimens and have yielded mixed results [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/7,19-22\">",
"     7,19-22",
"    </a>",
"    ]. As mentioned above, an open-label study of 80 premenopausal and postmenopausal women (most with normal androgen levels) that compared treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     cyproterone",
"    </a>",
"    acetate and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    found that both treatments appeared to be effective, and did not find a significant difference in efficacy between the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H633853661\">",
"     'Spironolactone'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In contrast, a randomized trial raised questions about the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     cyproterone acetate",
"    </a>",
"    for FPHL. In the one-year trial, 66 premenopausal women (many with acne, hirsutism, or menstrual cycle irregularities) were randomized to receive either topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    2% solution plus an oral contraceptive containing ethinyl estradiol and gestodene or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     cyproterone",
"    </a>",
"    acetate (50 mg per day for 20 days per menstrual cycle) plus an oral contraceptive containing ethinyl estradiol and 2 mg of cyproterone acetate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/20\">",
"     20",
"    </a>",
"    ]. While minoxidil appeared to be effective for inducing hair regrowth (change in hair count between first and last measurement = 7.7 &plusmn; 9.3), statistically significant hair regrowth did not occur in the cyproterone acetate group (change in hair count between first and last measurement = -0.2 &plusmn; 6.7). Among patients treated with cyproterone acetate, women with irregular menstrual cycles seemed to respond better than women without irregular menstrual cycles; however, this difference was not statistically significant.",
"   </p>",
"   <p>",
"    The dosing regimen for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     cyproterone acetate",
"    </a>",
"    for FPHL is not standardized. When used in the treatment of FPHL, some authors have suggested the following regimens for premenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      100 mg per day on days 5 to 15 of the menstrual cycle and 50 &mu;g of ethinyl estradiol on days 5 to 25",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     OR",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      50 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"       cyproterone acetate",
"      </a>",
"      on days 1 to 10 and 35 &mu;g on ethinyl estradiol on days 1 to 21",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Postmenopausal women may be treated with 50 mg daily [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     cyproterone acetate",
"    </a>",
"    include menstrual cycle irregularity, weight gain, breast tenderness, reduced libido, depression, and nausea [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H633853669\">",
"    <span class=\"h2\">",
"     5-alpha reductase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     Finasteride",
"    </a>",
"    is a type 2 5-alpha-reductase inhibitor that is frequently used in the treatment of male androgenetic alopecia. Finasteride inhibits the conversion of testosterone to dihydrotestosterone, thereby reducing the effects of dihydrotestosterone on hair follicles [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23336?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of androgenetic alopecia in men\", section on 'Finasteride'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Few studies have evaluated the efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    in women with FPHL, and the available studies have utilized varied treatment regimens and have found different results. Although a 12-month placebo-controlled randomized trial of 137 postmenopausal women with FPHL and normal serum androgen levels found that treatment with finasteride 1 mg per day did not seem to be of benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/25\">",
"     25",
"    </a>",
"    ], uncontrolled studies utilizing higher doses of finasteride (2.5 or 5 mg per day) have suggested that finasteride may be of benefit in some women without hyperandrogenism [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conflicting data also exist regarding the value of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    in hyperandrogenemic women with FPHL. A one-year open-label trial in which 36 premenopausal women with FPHL and hyperandrogenism were randomized to receive finasteride (5 mg per day),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    (250 mg per day), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     cyproterone acetate",
"    </a>",
"    (50 mg per day for 10 days per month) plus ethinyl estradiol (25 mcg for 20 days per month) found that the results achieved with finasteride were similar to those seen in 12 women who were recruited to the study but refused therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/19\">",
"     19",
"    </a>",
"    ]. In contrast, a case series of four women with hyperandrogenism and hair loss (two premenopausal and two postmenopausal) found that the condition stabilized or improved during finasteride therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to a recommendation for the routine use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    for FPHL, additional studies are necessary to clarify the population of women with FPHL who may benefit from treatment and to identify the most appropriate treatment regimen.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     Finasteride",
"    </a>",
"    is usually well-tolerated by women [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/25\">",
"     25",
"    </a>",
"    ]. Studies in men have included reports of reduced libido and breast swelling or tenderness [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/24\">",
"     24",
"    </a>",
"    ]. Finasteride is also teratogenic; the drug may induce feminization of a male fetus. Thus, treatment with finasteride should be avoided in women who are pregnant or considering becoming pregnant. When the drug is given to premenopausal women who may become pregnant, the use of reliable contraception is indicated.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"     Dutasteride",
"    </a>",
"    , a type 1 and type 2 5-alpha-reductase inhibitor, was reported as effective in a 46-year-old woman who had attained only minimal improvement in FPHL with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    . [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/27\">",
"     27",
"    </a>",
"    ]. Further study is necessary to determine the efficacy and safety of dutasteride in the treatment of FPHL [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H633865103\">",
"    <span class=\"h2\">",
"     Flutamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/23/4470?source=see_link\">",
"     Flutamide",
"    </a>",
"    is an antiandrogenic agent infrequently utilized for the treatment of FPHL. A few studies have found evidence in support of its efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/19,29,30\">",
"     19,29,30",
"    </a>",
"    ]. In a prospective cohort study of 101 premenopausal women with FPHL (including 12 with elevated testosterone levels at baseline) who were treated with flutamide (250 mg for one year, 125 mg for one year, then 62.5 mg per day for two years), statistically significant improvement in hair loss severity scores were detected within six months, and continued improvement was noted up to two years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/30\">",
"     30",
"    </a>",
"    ]. The mean percentage improvement was 15 percent at six months and 28 percent at two years. Flutamide was also reported to be effective in a premenopausal woman with normal androgen levels who failed to improve with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/31\">",
"     31",
"    </a>",
"    ]. The woman had hair regrowth when flutamide was added to topical minoxidil 5% applied daily.",
"   </p>",
"   <p>",
"    Potential side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    include reduced libido, gastrointestinal distress, and liver function test abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/30\">",
"     30",
"    </a>",
"    ]. Hepatic failure is a rare side effect and concern regarding this possibility has limited the use of flutamide therapy. However, significant elevations in transaminases were seen in only 4 percent of patients in the prospective cohort study, and the transaminase abnormalities resolved rapidly after treatment cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H633853692\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical interventions similar to those performed for male androgenetic alopecia are an option for women with FPHL who do not achieve a satisfactory response with pharmacological therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. Through the transplantation of terminal hairs from unaffected areas of the scalp to affected sites, patients can achieve cosmetically favorable improvements. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23336?source=see_link&amp;anchor=H335327#H335327\">",
"     \"Treatment of androgenetic alopecia in men\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H633855216\">",
"    <span class=\"h1\">",
"     OTHER THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 26-week unpublished device-controlled randomized trial found an increase in hair counts in women with FPHL who were treated with a low level laser device for 12 minutes three times weekly (HairMax laser comb) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/36\">",
"     36",
"    </a>",
"    ]. Further study is necessary to confirm the efficacy of low level therapy in FPHL. Low level laser therapy has also been used for male androgenetic alopecia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23336?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of androgenetic alopecia in men\", section on 'Light therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/42/41635?source=see_link\">",
"     Latanoprost",
"    </a>",
"    0.1%, a topical prostaglandin analog, was reported to increase hair density in a small randomized trial of men with androgenetic alopecia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/38\">",
"     38",
"    </a>",
"    ]. However, injections of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44115?source=see_link\">",
"     bimatoprost",
"    </a>",
"    , another prostaglandin analog, were not effective in a woman with FPHL [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/39\">",
"     39",
"    </a>",
"    ]. Additional study is necessary to determine whether prostaglandin analogues are of value in FPHL.",
"   </p>",
"   <p>",
"    The efficacy of mesotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/40\">",
"     40",
"    </a>",
"    ], estrogens, and supplements, such as iron,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"     biotin",
"    </a>",
"    , ginseng, saw palmetto, green tea, and caffeine on FPHL are unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14344/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H633853734\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once FPHL develops, the condition typically progresses over time, resulting in diminishing coverage of affected areas of the scalp by hair. Unlike male androgenetic alopecia, progression to complete baldness usually does not occur.",
"   </p>",
"   <p>",
"    Although topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    and other pharmacological therapies are effective in some women with FPHL, the response to treatment is variable. Treatment may result in no effect, the inhibition of further hair loss, or a variable degree of regrowth of hair. Since the response to treatment may be incomplete, initiating treatment at an early stage, prior to the development of extensive hair loss, is preferred. Pharmacological therapy must be continued indefinitely to maintain the response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H633857058\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Female pattern hair loss (FPHL) is a common form of nonscarring hair loss that typically occurs in adult women. A variety of topical and systemic therapies have been used for the management of this condition. The response to treatment varies. (See",
"      <a class=\"local\" href=\"#H633853598\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H633853734\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with FPHL who desire treatment, we suggest topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"       minoxidil",
"      </a>",
"      as first-line therapy (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). We often select minoxidil 5% solution (twice daily) or minoxidil 5% foam (once daily) over minoxidil 2% solution (twice daily) due to limited evidence that suggests that the higher concentrations may have slightly better efficacy. At least one year of treatment with minoxidil is required prior to drawing conclusions regarding treatment efficacy. (See",
"      <a class=\"local\" href=\"#H633853619\">",
"       'Topical minoxidil'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Data are limited on treatments other than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"       minoxidil",
"      </a>",
"      for FPHL. Systemic agents that inhibit androgen action or production, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"       cyproterone acetate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"       finasteride",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/23/4470?source=see_link\">",
"       flutamide",
"      </a>",
"      , may be useful in some patients. Further studies are necessary to define which women benefit from these therapies. (See",
"      <a class=\"local\" href=\"#H633853654\">",
"       'Second-line therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hair transplantation surgery can provide cosmetically favorable results in women with FPHL. Surgical intervention is an option for women who fail to achieve satisfactory improvement with medical therapy. (See",
"      <a class=\"local\" href=\"#H633853692\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Without treatment, the FPHL typically progresses slowly, though areas of complete baldness similar to those seen in male androgenetic alopecia usually do not occur. Because the response to treatment may be incomplete, initiating treatment early in the course of FPHL is preferred. (See",
"      <a class=\"local\" href=\"#H633853734\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/1\">",
"      Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol 2004; 150:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/2\">",
"      van Zuuren EJ, Fedorowicz Z, Carter B, et al. Interventions for female pattern hair loss. Cochrane Database Syst Rev 2012; 5:CD007628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/3\">",
"      Lucky AW, Piacquadio DJ, Ditre CM, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol 2004; 50:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/4\">",
"      Blume-Peytavi U, Hillmann K, Dietz E, et al. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol 2011; 65:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/5\">",
"      Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol 2005; 52:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/6\">",
"      Blumeyer A, Tosti A, Messenger A, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges 2011; 9 Suppl 6:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/7\">",
"      Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol 2005; 152:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/8\">",
"      Iorizzo M, Vincenzi C, Voudouris S, et al. Finasteride treatment of female pattern hair loss. Arch Dermatol 2006; 142:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/9\">",
"      Yeon JH, Jung JY, Choi JW, et al. 5 mg/day finasteride treatment for normoandrogenic Asian women with female pattern hair loss. J Eur Acad Dermatol Venereol 2011; 25:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/10\">",
"      Tr&uuml;eb RM, Swiss Trichology Study Group. Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women. Dermatology 2004; 209:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/11\">",
"      Tosti A, Camacho-Martinez F, Dawber R. Management of androgenetic alopecia. J Eur Acad Dermatol Venereol 1999; 12:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/12\">",
"      Rathnayake D, Sinclair R. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Dermatol Clin 2010; 28:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/13\">",
"      Sinclair R, Patel M, Dawson TL Jr, et al. Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. Br J Dermatol 2011; 165 Suppl 3:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/14\">",
"      Burke BM, Cunliffe WJ. Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. Br J Dermatol 1985; 112:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/15\">",
"      Yazdabadi A, Green J, Sinclair R. Successful treatment of female-pattern hair loss with spironolactone in a 9-year-old girl. Australas J Dermatol 2009; 50:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/16\">",
"      Hoedemaker C, van Egmond S, Sinclair R. Treatment of female pattern hair loss with a combination of spironolactone and minoxidil. Australas J Dermatol 2007; 48:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/17\">",
"      Adamopoulos DA, Karamertzanis M, Nicopoulou S, Gregoriou A. Beneficial effect of spironolactone on androgenic alopecia. Clin Endocrinol (Oxf) 1997; 47:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/18\">",
"      Camacho-Mart&iacute;nez FM. Hair loss in women. Semin Cutan Med Surg 2009; 28:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/19\">",
"      Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. Fertil Steril 2003; 79:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/20\">",
"      Vexiau P, Chaspoux C, Boudou P, et al. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br J Dermatol 2002; 146:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/21\">",
"      Peereboom-Wynia JD, van der Willigen AH, van Joost T, Stolz E. The effect of cyproterone acetate on hair roots and hair shaft diameter in androgenetic alopecia in females. Acta Derm Venereol 1989; 69:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/22\">",
"      Rushton DH, Ramsay ID. The importance of adequate serum ferritin levels during oral cyproterone acetate and ethinyl oestradiol treatment of diffuse androgen-dependent alopecia in women. Clin Endocrinol (Oxf) 1992; 36:421.",
"     </a>",
"    </li>",
"    <li>",
"     Otberg N, Shapiro J. Hair growth disorders. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, et al (Eds), McGraw-Hill, New York 2012. Vol 1, p.979.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/24\">",
"      Stout SM, Stumpf JL. Finasteride treatment of hair loss in women. Ann Pharmacother 2010; 44:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/25\">",
"      Price VH, Roberts JL, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol 2000; 43:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/26\">",
"      Shum KW, Cullen DR, Messenger AG. Hair loss in women with hyperandrogenism: four cases responding to finasteride. J Am Acad Dermatol 2002; 47:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/27\">",
"      Olszewska M, Rudnicka L. Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol 2005; 4:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/28\">",
"      Scheinfeld N. A review of hormonal therapy for female pattern (androgenic) alopecia. Dermatol Online J 2008; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/29\">",
"      Cusan L, Dupont A, Gomez JL, et al. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril 1994; 61:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/30\">",
"      Paradisi R, Porcu E, Fabbri R, et al. Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss. Ann Pharmacother 2011; 45:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/31\">",
"      Yazdabadi A, Sinclair R. Treatment of female pattern hair loss with the androgen receptor antagonist flutamide. Australas J Dermatol 2011; 52:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/32\">",
"      Epstein JS. The treatment of female pattern hair loss and other applications of surgical hair restoration in women. Facial Plast Surg Clin North Am 2004; 12:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/33\">",
"      Unger WP, Unger RH. Hair transplanting: an important but often forgotten treatment for female pattern hair loss. J Am Acad Dermatol 2003; 49:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/34\">",
"      Avram MR. Hair transplantation for men and women. Semin Cutan Med Surg 2006; 25:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/35\">",
"      Callender VD, McMichael AJ, Cohen GF. Medical and surgical therapies for alopecias in black women. Dermatol Ther 2004; 17:164.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.clinicaltrials.gov/ct2/show/results/NCT00981461?term=NCT00981461&amp;rank=1&amp;sect=X6015#outcome1 (Accessed on October 01, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/37\">",
"      Leavitt M, Charles G, Heyman E, Michaels D. HairMax LaserComb laser phototherapy device in the treatment of male androgenetic alopecia: A randomized, double-blind, sham device-controlled, multicentre trial. Clin Drug Investig 2009; 29:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/38\">",
"      Blume-Peytavi U, L&ouml;nnfors S, Hillmann K, Garcia Bartels N. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol 2012; 66:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/39\">",
"      Emer JJ, Stevenson ML, Markowitz O. Novel treatment of female-pattern androgenetic alopecia with injected bimatoprost 0.03% solution. J Drugs Dermatol 2011; 10:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14344/abstract/40\">",
"      Mysore V. Mesotherapy in Management of Hairloss - Is it of Any Use? Int J Trichology 2010; 2:45.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86648 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-76D4E16EBB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_0_14344=[""].join("\n");
var outline_f14_0_14344=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H633857058\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H633853598\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H633853605\">",
"      GENERAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H633853612\">",
"      FIRST-LINE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H633853619\">",
"      Topical minoxidil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H633853626\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H633853633\">",
"      - Product selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H633853640\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H633853647\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H633853654\">",
"      SECOND-LINE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H633853661\">",
"      Spironolactone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H633865258\">",
"      Cyproterone acetate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H633853669\">",
"      5-alpha reductase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H633865103\">",
"      Flutamide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H633853692\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H633855216\">",
"      OTHER THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H633853734\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H633857058\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10856?source=related_link\">",
"      Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31752?source=related_link\">",
"      Female pattern hair loss (androgenetic alopecia in women): Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23336?source=related_link\">",
"      Treatment of androgenetic alopecia in men",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_0_14345="Treatment of growth hormone deficiency in children";
var content_f14_0_14345=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of growth hormone deficiency in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/0/14345/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/0/14345/contributors\">",
"     Alan D Rogol, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/0/14345/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/0/14345/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/0/14345/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/0/14345/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/0/14345/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of the pituitary gland for growth was recognized in 1886, when Mairie noted the association between pituitary tumors and symptoms and signs of acromegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/1\">",
"     1",
"    </a>",
"    ]. The presence of a growth-promoting factor in the hypophysis was demonstrated in 1909, when Aschner demonstrated that removal of the pituitary from puppies causes severe growth retardation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It was not until 1921, however, that a positive effect of the hypophysis on growth was demonstrated by studies in which intraperitoneal administration of a saline extract of anterior pituitary lobes was found to increase body weight in rats [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/3\">",
"     3",
"    </a>",
"    ]. In a classic series of experiments in 1930, the necessity for the hypophysis for normal growth was conclusively demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/4\">",
"     4",
"    </a>",
"    ]. Ablation of the hypophysis resulted in the cessation of growth, which was restored by anterior pituitary lobe transplants. When injected intraperitoneally, a saline suspension of anterior lobes stimulated growth in hypophysectomized rats but had no effect on the atrophied reproductive organs. &nbsp;",
"   </p>",
"   <p>",
"    The indications for and efficacy of exogenous growth hormone (GH) treatment in children with growth hormone deficiency (GHD) are reviewed here. The diagnostic approach to the child with short stature and the diagnosis of growth hormone deficiency are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=see_link\">",
"     \"Causes of short stature\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18376?source=see_link\">",
"     \"Diagnostic approach to short stature\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/82?source=see_link\">",
"     \"Diagnosis of growth hormone deficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GH therapy is also used for several other specific indications in children and adolescents; these uses are discussed in separate topic reviews:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Growth failure associated with chronic kidney disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27881?source=see_link\">",
"       \"Growth hormone treatment in children with chronic kidney disease and postrenal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Short stature associated with Turner syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14329?source=see_link\">",
"       \"Management of Turner syndrome (gonadal dysgenesis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Short stature associated with being born small for gestational age. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/37/3672?source=see_link\">",
"       \"Growth hormone treatment for children born small for gestational age\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Short stature associated with Prader-Willi syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/8/134?source=see_link\">",
"       \"Clinical features, diagnosis, and treatment of Prader-Willi syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Idiopathic short stature. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18248?source=see_link\">",
"       \"Growth hormone treatment for idiopathic short stature\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Short stature associated with mutations in the Short Stature Homeobox (SHOX) gene. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=see_link\">",
"       \"Causes of short stature\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Short stature associated with Noonan syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=see_link&amp;anchor=H19#H19\">",
"       \"Causes of short stature\", section on 'Noonan syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSIOLOGIC ACTIONS OF GROWTH HORMONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;GH affects many of the metabolic processes carried out by somatic cells. The best known is the effect of increasing body mass. Although generalized growth is stimulated, it is not evenly distributed among the protein, lipid, and carbohydrate compartments. Body protein content and bone mass increase, total body fat content decreases, and there is an increase in plasma and liver lipid content on account of mobilization of free fatty acids (FFA) from peripheral fat stores. The ability of insulin to promote fatty acid synthesis is antagonized by GH.",
"   </p>",
"   <p>",
"    GH stimulates cartilage growth. This is most evident as a widening of the epiphyseal plate, and is associated with an increase in amino acid incorporation into cartilage and bone [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/5\">",
"     5",
"    </a>",
"    ]. GH also stimulates the uptake of sulfate by cartilage in vivo, but not in vitro. However, in vitro sulfate uptake is stimulated by serum from normal or hypophysectomized animals treated with GH. This \"sulfation factor\" proved to be the insulin-like growth factor I (IGF-I) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/7/3192?source=see_link\">",
"     \"Physiology of insulin-like growth factor I\"",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF GH DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;GHD is a clinical diagnosis, based on auxological features (ie, a comparison of a child's growth pattern to established norms), and confirmed by biochemical testing. Once the decision to evaluate a short child has been made, many different tests can be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/82?source=see_link\">",
"     \"Diagnosis of growth hormone deficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If GHD is congenital and complete, the diagnosis is relatively easy to confirm. Affected children present with early severe growth failure, delayed bone age (if the diagnosis is significantly delayed), central distribution of body fat, and very low serum concentrations of GH, IGF-I, and its major binding protein, IGFBP-3 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/8\">",
"     8",
"    </a>",
"    ]. Infants are prone to hypoglycemia, prolonged jaundice, microphallus in males, and giant cell hepatitis. If hypoglycemia is noted, growth hormone treatment should be initiated to protect against further episodes. &nbsp;",
"   </p>",
"   <p>",
"    For children with milder manifestations of GHD, it may be more difficult to establish the diagnosis. Nonetheless, once the diagnosis is confirmed, such children can and should be treated with GH until linear growth ceases. Treatment should be started as soon as the diagnosis of GHD is confirmed because the growth response is more robust when treatment is started at a younger age. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Dosing and monitoring'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H4132357\">",
"     'Linear growth'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREPARATIONS OF GROWTH HORMONE FOR THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several pharmacologic preparations of GH are approved for treatment of GHD in children, and others are still being tested:",
"   </p>",
"   <p>",
"    Most children with GHD are treated with aqueous solutions of biosynthetic (recombinant) GH, which are administered by subcutaneous injection. Several brands of GH have been available for subcutaneous administration for many years, and most information about GH treatment comes from these preparations. They are equally biopotent and have the same natural sequence structure. Most are available in multiple-dose pen devices that facilitate administration. Daily therapy is more effective than three times a week at the same total weekly dose [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Sustained release preparations of GH for deep subcutaneous administration are in development and may be available in a few countries outside of the United States. These are designed for administration once weekly [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. One preparation (LB03002, which uses a proprietary delivery technology) has been directly compared to daily administration of aqueous preparations. In a long-term trial, LB03002 maintained expected growth rates for patients continuously treated for 24 months as well as in patients treated for 12 months who were switched from daily therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/14\">",
"     14",
"    </a>",
"    ]. IGF-1 levels continued to increase toward the normal range in both groups during LB03002 treatment, a key marker of efficacy and safety in growth hormone therapy. The children displayed sustained growth potential, without excessive bone maturation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DOSING AND MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend an initial dose of aqueous recombinant GH of approximately 40",
"    <span class=\"nowrap\">",
"     micrograms/kg/day,",
"    </span>",
"    given once daily by subcutaneous injection. Treatment should be started at the youngest possible age to achieve the best growth response. Children with chronic kidney disease or Turner's syndrome are given slightly higher doses because they have a degree of growth hormone resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27881?source=see_link\">",
"     \"Growth hormone treatment in children with chronic kidney disease and postrenal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14329?source=see_link&amp;anchor=H6#H6\">",
"     \"Management of Turner syndrome (gonadal dysgenesis)\", section on 'Growth hormone therapy'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Administration of GH in the evening is sometimes suggested based on the rationale that this produces more physiologic patterns of GH. However, there is no evidence that this approach is more effective. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H562846\">",
"    <span class=\"h2\">",
"     Dose adjustment based on IGF-I response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the variability in individual responses to GH therapy, we measure levels of IGF-I approximately four weeks after beginning therapy or changing the dose, and adjust the growth hormone dose based upon the growth response and the level of IGF-I. The therapeutic goal is to achieve levels of IGF-I that are slightly higher than average (approximately 1 SD above the mean for age",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Tanner stage of pubertal development), because growth velocity is usually greater at these IGF-I levels than at IGF-I levels at or below the mean. This approach is not universally used, but is supported by small randomized trials in which GH doses were adjusted based on IGF-I levels [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/15\">",
"     15",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H562861\">",
"    <span class=\"h2\">",
"     Growth response",
"    </span>",
"    &nbsp;&mdash;&nbsp;A child&rsquo;s height velocity should be monitored to determine whether the growth response is adequate. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ideally, the child&rsquo;s growth should be compared to curves generated from a population of similarly treated children with GHD; we generally target a height velocity above the 75",
"      <sup>",
"       th",
"      </sup>",
"      percentile curve (",
"      <a class=\"graphic graphic_figure graphicRef76882 \" href=\"UTD.htm?13/25/13715\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/16\">",
"       16",
"      </a>",
"      ] or greater than 1 SD above the mean height velocity (",
"      <a class=\"graphic graphic_figure graphicRef75268 \" href=\"UTD.htm?19/2/19489\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Alternatively, the child&rsquo;s height velocity can be compared to curves showing normal height velocity for age in children without GHD, but this is a much less accurate way to assess for an adequate growth response. In this case, the 75",
"      <sup>",
"       th",
"      </sup>",
"      percentile curve for height velocity is also an appropriate target to define a &ldquo;good&rdquo; growth response to GH. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18376?source=see_link&amp;anchor=H9#H9\">",
"       \"Diagnostic approach to short stature\", section on 'Although the child is short, is his or her growth velocity normal or impaired?'",
"      </a>",
"      .) &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H562868\">",
"    <span class=\"h2\">",
"     Ongoing monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with an adequate IGF-I response four weeks after beginning treatment (ie, IGF-I levels approximately 1 SD above the mean for age",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Tanner stage of development), we recheck length or height at least every 4 to 6 months (or every 2 to 3 months in infants), and measure IGF-I levels every 6 to 12 months. We also measure thyroid function annually to assess for treatment-emergent hypothyroidism, although this is uncommon unless the patient has associated hypopituitarism. Free T4 should be measured, because this type of hypothyroidism is usually central and would not be detectable with TSH screening alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H562981\">",
"    <span class=\"h2\">",
"     Inadequate response",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a child does not have an adequate growth response to GH therapy, possible causes include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Poor adherence to GH treatment",
"     </li>",
"     <li>",
"      Incorrect diagnosis of GHD",
"     </li>",
"     <li>",
"      Subtherapeutic dose of GH",
"     </li>",
"     <li>",
"      The patient has GHD, but has concurrent mild GH insensitivity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To distinguish among these possibilities, the clinician should review the regimen with the patient and family, review the data that led to the initial diagnosis of GHD, and check IGF-I levels. Lack of response to adequately-dosed GH treatment (as measured by inadequate growth and low IGF-I levels) suggests relative insensitivity to the effects of GH, which may respond to higher doses of GH. &nbsp;",
"   </p>",
"   <p>",
"    Patients with GHD due to a GH gene deletion occasionally develop neutralizing antibodies to administered GH relatively soon after initiation of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Thus, these patients manifest an acquired GH insensitivity and respond to treatment with recombinant human IGF-I (mecasermin). This possibility should be considered in patients who, after an initial typical growth response to GH treatment over the first three to six months, suddenly have a diminution in their growth rate and low levels of IGF-I despite adequate dosing of GH. The diagnosis is supported by serum testing for anti human GH antibodies,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by genetic testing to determine whether the patient&rsquo;s GH deficiency is caused by a GH gene deletion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39270?source=see_link\">",
"     \"Growth hormone insensitivity syndromes\"",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RESPONSE TO GROWTH HORMONE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When given for the treatment of GHD, GH therapy is clearly effective; if GH is administered at an early age, patients can achieve adult height within the midparental target height range [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4132357\">",
"    <span class=\"h2\">",
"     Linear growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knowledge of the quantitative relationship between growth velocity and dose (and schedule) of GH administration would be valuable if it could be determined accurately and precisely. Even more valuable would be a reliable method to predict adult height as a function of the dose of GH. However, this has proven impossible, because of differences in responsiveness and in treatment regimens. The growth response demonstrated in large studies to date is not linear (ie, the increase in growth rate is not proportional to the increase in dose) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors that predict the response to GH therapy have been derived from two very large databases: the Pfizer International Growth Database (previously known as the Kabi International Growth Study, KIGS) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/23\">",
"     23",
"    </a>",
"    ] and National Childhood Growth Study (NCGS) in North America [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A model based on KIGS data found that the following factors predicted a better response to growth hormone treatment during the first year of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/23\">",
"     23",
"    </a>",
"    ]: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lower maximum growth hormone level in response to provocative stimulation testing",
"     </li>",
"     <li>",
"      Younger age",
"     </li>",
"     <li>",
"      Greater deviation from predicted height at baseline (difference between the child&rsquo;s height SD score and the midparental height SD score)",
"     </li>",
"     <li>",
"      Body weight",
"     </li>",
"     <li>",
"      Growth hormone dose",
"     </li>",
"     <li>",
"      Birth weight",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, these factors predicted 61 percent of the variance in growth response during the first year of treatment. For the second, third, and fourth years of treatment, positive predictors of growth response were height velocity during the previous year, body weight, younger age, and growth hormone dose. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Other variables that affect the response include duration of treatment and such difficult-to-study factors as diet [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/24\">",
"     24",
"    </a>",
"    ], exercise, and psychological well-being.",
"   </p>",
"   <p>",
"    The dose responses for children with chronic kidney disease or Turner's syndrome and Noonan syndrome are even less predictable. These are considered GH \"resistance\" syndromes requiring a higher dose of GH than recommended for children with GHD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27881?source=see_link\">",
"     \"Growth hormone treatment in children with chronic kidney disease and postrenal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14329?source=see_link&amp;anchor=H5#H5\">",
"     \"Management of Turner syndrome (gonadal dysgenesis)\", section on 'Short stature'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=see_link&amp;anchor=H19#H19\">",
"     \"Causes of short stature\", section on 'Noonan syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Puberty",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a prepubertal patient initially responds well to GH treatment, but then fails to achieve the expected height velocity of the pubertal growth spurt, they may benefit from a temporary increase in GH dose (eg, to 70 to 100",
"    <span class=\"nowrap\">",
"     micrograms/kg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/25\">",
"     25",
"    </a>",
"    ]. In a randomized trial, 48 children with GHD completed a study comparing either standard dose GH (43",
"    <span class=\"nowrap\">",
"     micrograms/kg/day)",
"    </span>",
"    or high dose GH (70",
"    <span class=\"nowrap\">",
"     micrograms/kg/day)",
"    </span>",
"    during puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/26\">",
"     26",
"    </a>",
"    ]. By the end of the pubertal growth spurt, children treated with high dose GH were approximately 3.6 cm taller than those treated with standard dose GH. The high dose of GH did not measurably increase the rate of skeletal maturation or glucose intolerance, and in some cases was associated with marked elevations in serum IGF-I levels. Hence, great care must be employed when using such high doses of GH. Of note, these findings may not be relevant to children whose dose of GH is periodically readjusted during GH therapy based on serum IGF-I levels, as we suggest above. The modest gains in height achieved by giving higher doses of GH during puberty must be balanced against the substantial costs of the additional GH. In general, effective treatment with GH prior to puberty is more effective and cost-effective than efforts to boost growth during puberty. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Dosing and monitoring'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    In cases in which GH treatment is not begun until adolescence, the child may not achieve desired height with GH therapy alone because there already may be significant partial closure of the growth plates. This has prompted study of adjunctive therapy to delay epiphyseal maturation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with GHD starting treatment in early- to mid-puberty, a few studies suggest that the addition of a gonadotropin-releasing hormone (GnRH) agonist to GH treatment may result in a taller near-adult height [",
"      <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/27-29\">",
"       27-29",
"      </a>",
"      ]. However, the widespread use of this approach in children with GH-deficiency remains controversial: although GnRH agonists can theoretically increase adult height by delaying epiphyseal closure, thereby allowing more time for growth during puberty, long-term treatment (&gt;3 years) is likely required to accomplish this goal. Furthermore, it has not been established that GnRH agonist treatment yields greater increases in height compared with GH treatment alone if GH treatment is initiated prior to puberty. In addition, the clinician must consider multiple issues when considering addition of GnRH agonist therapy, including risks of potential reduced bone mineralization, psychological effects of halting puberty, and cost-benefit analysis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. Instead, it is preferable to make a timely diagnosis of GH deficiency and initiate GH therapy prior to puberty; this usually provides sufficient height gains such that GnRH agonist therapy is not necessary. &nbsp;",
"     </li>",
"     <li>",
"      An alternative approach to delay epiphyseal fusion is to reduce the effect of estrogen, which promotes the closure of growth plates. Data on therapies directed toward either decreasing estrogen synthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/32,33\">",
"       32,33",
"      </a>",
"      ] or blocking estrogen effects [",
"      <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/34\">",
"       34",
"      </a>",
"      ] are limited. In one study of adolescent boys with GHD on GH therapy, addition of anastrazole, a third-generation aromatase inhibitor, for two to three years resulted in a projected mean height gain of 2.67 inches (6.8 cm) compared to a group treated only with GH. This treatment may offer an alternative in promoting growth in GH-deficient boys in puberty. Long-term follow up still is needed to fully examine the long-term safety and efficacy of this approach [",
"      <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bone mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone mass increases at an accelerated rate during puberty, and peak cortical and trabecular bone mass are reached early in the third decade. Peak bone mass is important because it is a major determinant of adult bone mass and therefore susceptible to osteoporosis later in life [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40040?source=see_link\">",
"     \"Calcium requirements in adolescents\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    In GH-deficient children, bone mass is low, as compared with age and size-matched control children, and it increases at an accelerated rate during treatment with GH. In one study of GH-deficient boys and girls, GH therapy for five years resulted in an increase of more than 1.5 SD in bone density Z-score [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/37\">",
"     37",
"    </a>",
"    ]. These findings suggest that GH therapy increases bone mass and the progression toward peak bone mass in children with GHD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/38\">",
"     38",
"    </a>",
"    ]. Thus, low bone mass in adults can be a consequence of childhood-onset as well as adult-onset GHD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, GH treatment for children and adolescents with GHD has an important role in increasing bone mass, and the attainment of an increased (normal) peak bone mass may be considered an additional goal of therapy. It is therefore important to consider the continuation of GH treatment even after linear growth has ceased until full skeletal (and body composition) development has occurred, and possibly beyond [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1833?source=see_link&amp;anchor=H3#H3\">",
"     \"Growth hormone deficiency in adults\", section on 'Clinical manifestations and benefits of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;GH treatment in children has generally been safe [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/42-44\">",
"     42-44",
"    </a>",
"    ], with the exception of Creutzfeldt-Jakob disease in children who received GH extracted from human pituitary tissue prior to the development of recombinant human GH [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among children treated with recombinant GH, there appears to be a slightly higher risk of developing idiopathic intracranial hypertension (pseudotumor cerebri), increased intraocular pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/47\">",
"     47",
"    </a>",
"    ], slipped capital femoral epiphysis, and worsening of existing scoliosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/42\">",
"     42",
"    </a>",
"    ]. Whether these are true side effects of GH itself or whether some are related to the rapid growth induced by GH remains unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15769?source=see_link\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other rare adverse effects are pancreatitis, transient gynecomastia, and an increase in the growth and pigmentation of nevi, without malignant degeneration (",
"    <a class=\"graphic graphic_table graphicRef79365 \" href=\"UTD.htm?21/26/21931\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/42,48\">",
"     42,48",
"    </a>",
"    ]. Carpal tunnel syndrome, edema, and arthralgia are common in adults undergoing growth hormone treatment but are unusual in children. Most usually occur soon after therapy is initiated, and some of these effects are probably caused by sodium and water retention [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/49\">",
"     49",
"    </a>",
"    ]. With the purified biosynthetic GH that is now used, antibody generation that blocks GH action is rare.",
"   </p>",
"   <p>",
"    Development of insulin resistance and disorders of glucose intolerance may occur in children receiving growth hormone therapy, but the clinical significance appears to be low. An international surveillance program of 23,333 children and adolescents receiving GH identified 18 new cases of type 2 diabetes mellitus and 14 of impaired glucose tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/50\">",
"     50",
"    </a>",
"    ]. Although these numbers were higher than expected based upon historical controls, the number of patients affected is small.",
"   </p>",
"   <p>",
"    Concerns have been raised about a possible role for GH or its mediator IGF-I in cancer risk; these concerns are primarily based on observations that IGF-I levels are associated with increased risks for breast or prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/51\">",
"     51",
"    </a>",
"    ]. One report of children and adults treated with human pituitary GH from 1959 to 1985 suggested an increased long-term risk of colorectal cancer or Hodgkin&rsquo;s disease, but because these are rare events a larger cohort would be required to draw firm conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/52\">",
"     52",
"    </a>",
"    ]. Furthermore, these results may not be generalizable to recombinant preparations of GH and modern treatment regimens, especially if doses are adjusted to ensure that IGF-I levels are kept within the normal range. Analyses of databases following patients who have been treated with GH in the modern era do not suggest an increased risk of malignancy after GH treatment during childhood for GH deficiency, although the length of follow up is still relatively brief [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. In particular, the risk of leukemia has been extensively studied, both in the United States and Japan, and no significant increase in new cases or in the relapse of previous ones has been found despite several hundred thousand patient-years of exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. Similarly, treatment of childhood cancer survivors with GH does not appear to increase the risk for secondary malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/60,61\">",
"     60,61",
"    </a>",
"    ], except for the development of benign meningiomas after radiation treatment of certain primary brain tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/62\">",
"     62",
"    </a>",
"    ]. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DURATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;GH therapy is generally continued at least until linear growth decreases to less than 2.0 to 2.5 cm (1",
"    <span class=\"nowrap\">",
"     inch)/year.",
"    </span>",
"    Patients should then be retested for GHD to determine if treatment should be continued into adulthood for metabolic indications.",
"   </p>",
"   <p>",
"    A majority of individuals who had idiopathic, isolated GHD in childhood have normal GH secretion during late adolescence or young adulthood, presumably because of the stimulatory effects of gonadal steroid hormones on the hypothalamic-pituitary axis for GH secretion. In two similar studies, 78 and 67 percent of children with idiopathic, isolated GHD (a majority of whom had partial GHD initially) had normal serum GH responses to insulin-induced hypoglycemia at the completion of their GH therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    One study suggests that normalization of GH secretion often occurs prior to cessation of growth, and that shorter courses of GH are effective in selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/65\">",
"     65",
"    </a>",
"    ]. In this study, 69 subjects with GHD diagnosed prior to puberty were retested after initiation of puberty and at least two years of GH treatment (mean age at retesting 12.4 years for girls, 13.5 years for boys). One-third of the children had normal GH secretion at this time and therapy was suspended; for the remainder of the children, treatment was continued until growth ceased. Adult height was similar in both groups.",
"   </p>",
"   <p>",
"    These findings and those of other studies make it mandatory to retest most GH-deficient children after completion of growth, because only a small proportion may benefit from GH replacement therapy as adults. Some patients may become GH sufficient during early puberty, so earlier retesting may be worthwhile [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/65\">",
"     65",
"    </a>",
"    ]. In contrast, children with genetic GHD, multiple pituitary hormone deficiencies (which are usually caused by pituitary dysfunction),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    those with structural defects in the hypothalamic-pituitary region on magnetic resonance imaging (MRI) rarely recover the ability to secrete GH as an adult and may not need to undergo retesting for GHD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/0/14345/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1833?source=see_link\">",
"     \"Growth hormone deficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     GROWTH HORMONE INSENSITIVITY SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth hormone insensitivity (GHI) syndrome, also known as Laron syndrome, is a group of inherited disorders with mutations that affect the growth hormone receptor (GHR) or distal components of the post-GHR signaling cascade. Patients with GHI have normal or elevated circulating serum GH levels but low levels of IGF-I and IGFBP-3. This syndrome is discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39270?source=see_link\">",
"     \"Growth hormone insensitivity syndromes\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/12/3266?source=see_link\">",
"       \"Patient information: My child is short (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4131736\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Growth hormone (GH) promotes linear growth in children by stimulating cartilage growth, particularly at the epiphyseal plate. In addition, GH increases lean body mass and bone mass, and reduces fat mass, while increasing plasma and liver lipid content. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Physiologic actions of growth hormone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If growth hormone deficiency (GHD) is congenital and complete, the diagnosis is relatively easy to confirm. Affected children present with severe growth failure and very low serum concentrations of growth hormone, IGF-I, and its major binding protein, IGFBP-3. If diagnosed in infancy, they may also manifest hypoglycemia, prolonged jaundice, microphallus in males, and giant cell hepatitis. In those diagnosed late, delayed bone age is characteristic. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis of GH deficiency'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/5/82?source=see_link\">",
"       \"Diagnosis of growth hormone deficiency in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For children diagnosed with GHD we recommend treating with recombinant GH as compared with no treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The starting dose of GH is approximately 40",
"      <span class=\"nowrap\">",
"       micrograms/kg/day,",
"      </span>",
"      given subcutaneously once daily. Treatment should be started at the youngest possible age, to achieve the best growth response. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Preparations of growth hormone for therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Dosing and monitoring'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      We suggest adjusting the dose of GH based on levels of IGF-I and growth response, rather than continuing with the initial weight-based dose (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). To do this, we monitor height and IGF-I levels four weeks after starting or changing the dose of GH, and adjust the GH dose accordingly. The goal is to achieve an IGF-I level slightly higher than average (approximately 1 SD above the mean for age",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      Tanner stage of pubertal development), because growth velocity is greater at these IGF-I levels. Growth velocity is monitored at three to six month intervals; the goal for linear growth is above the average growth velocity for age. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Dosing and monitoring'",
"      </a>",
"      above.) &nbsp; &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      Predictors of a good height response to GH treatment include younger age at the start of therapy and greater deviation of target height (genetic potential) from actual height. In addition, a more frequent dosing schedule and higher dose of GH tend to correlate with improved growth outcomes, but this relationship is not linear. (See",
"      <a class=\"local\" href=\"#H4132357\">",
"       'Linear growth'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      For children who are not likely to achieve an adequate height response to GH because their growth plates are nearing closure, adjunctive therapy to delay epiphyseal maturation may be considered, but the efficacy and safety of these approaches are not well established. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Puberty'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend continuing GH therapy at least until linear growth is nearly complete (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ) (eg, decreased to less than 2.0 to 2.5",
"      <span class=\"nowrap\">",
"       cm/year).",
"      </span>",
"      Patients should then be re-tested for GHD to determine if treatment should be continued into adulthood. Most individuals with isolated GHD in childhood have normal GH secretion during adulthood, presumably because of the stimulatory effects of gonadal steroid hormones on the hypothalamic-pituitary axis for GH secretion. By contrast, children with genetic forms of GHD, multiple pituitary hormone deficiencies,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      those with structural abnormalities of the hypothalamic-pituitary region rarely become GH sufficient and hence probably do not need to be retested for GHD. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Duration of therapy'",
"      </a>",
"      above.) &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/1\">",
"      Marie P. Hypertrophie singuli&eacute;re non cong&eacute;nitale des extr&eacute;mit&eacute;s sup&eacute;rieures, inf&eacute;rieures et c&eacute;phaliques. Rev Med 1886; 6:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/2\">",
"      Aschner B. Demonstration von Hunden nach Exirpation der Hypohyse. Wien Klin Wochenschr 1909; 22:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/3\">",
"      Evans HE, Long JA. The effect of the anterior lobe administered intraperitoneally upon growth, maturity and oestrus cycles of the rat. Anat Rec 1921; 21:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/4\">",
"      Smith PE. Hypophysectomy and replacement therapy in the rat. Am J Anat 1930; 45:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/5\">",
"      MURPHY WR, DAUGHADAY WH, HARTNETT C. The effect of hypophysectomy and growth hormone on the incorporation of labeled sulfate into tibial epiphyseal and nasal cartilage of the rat. J Lab Clin Med 1956; 47:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/6\">",
"      SALMON WD Jr, DAUGHADAY WH. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 1957; 49:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/7\">",
"      Kaplan SA, Cohen P. The somatomedin hypothesis 2007: 50 years later. J Clin Endocrinol Metab 2007; 92:4529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/8\">",
"      Rosenfeld RG, Albertsson-Wikland K, Cassorla F, et al. Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab 1995; 80:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/9\">",
"      de Muinck Keizer-Schrama SM, Rikken B, Wynne HJ, et al. Dose-response study of biosynthetic human growth hormone (GH) in GH-deficient children: effects on auxological and biochemical parameters. Dutch Growth Hormone Working Group. J Clin Endocrinol Metab 1992; 74:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/10\">",
"      Blethen SL, Compton P, Lippe BM, et al. Factors predicting the response to growth hormone (GH) therapy in prepubertal children with GH deficiency. J Clin Endocrinol Metab 1993; 76:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/11\">",
"      Albertsson-Wikland K. The effect of human growth hormone injection frequency on linear growth rate. Acta Paediatr Scand Suppl 1987; 337:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/12\">",
"      MacGillivray MH, Baptista J, Johanson A. Outcome of a four-year randomized study of daily versus three times weekly somatropin treatment in prepubertal naive growth hormone-deficient children. Genentech Study Group. J Clin Endocrinol Metab 1996; 81:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/13\">",
"      Peter F, Savoy C, Ji HJ, et al. Pharmacokinetic and pharmacodynamic profile of a new sustained-release GH formulation, LB03002, in children with GH deficiency. Eur J Endocrinol 2009; 160:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/14\">",
"      P&eacute;ter F, Bidlingmaier M, Savoy C, et al. Three-year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD). J Clin Endocrinol Metab 2012; 97:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/15\">",
"      Cohen P, Germak J, Rogol AD, et al. Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children. J Clin Endocrinol Metab 2010; 95:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/16\">",
"      Ranke MB, Lindberg A, KIGS International Board. Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables. J Clin Endocrinol Metab 2010; 95:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/17\">",
"      Bakker B, Frane J, Anhalt H, et al. Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children. J Clin Endocrinol Metab 2008; 93:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/18\">",
"      Kemp SF. Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options. BioDrugs 2009; 23:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/19\">",
"      Chernausek SD, Backeljauw PF, Frane J, et al. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 2007; 92:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/20\">",
"      Root AW, Kemp SF, Rundle AC, et al. Effect of long-term recombinant growth hormone therapy in children--the National Cooperative Growth Study, USA, 1985-1994. J Pediatr Endocrinol Metab 1998; 11:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/21\">",
"      Reiter EO, Price DA, Wilton P, et al. Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database. J Clin Endocrinol Metab 2006; 91:2047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/22\">",
"      Frasier SD, Costin G, Lippe BM, et al. A dose-response curve for human growth hormone. J Clin Endocrinol Metab 1981; 53:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/23\">",
"      Ranke MB, Lindberg A, Chatelain P, et al. Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study. J Clin Endocrinol Metab 1999; 84:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/24\">",
"      Zadik Z, Sinai T, Zung A, Reifen R. Effect of nutrition on growth in short stature before and during growth-hormone therapy. Pediatrics 2005; 116:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/25\">",
"      Gharib H, Cook DM, Saenger PH, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children--2003 update. Endocr Pract 2003; 9:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/26\">",
"      Mauras N, Attie KM, Reiter EO, et al. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group. J Clin Endocrinol Metab 2000; 85:3653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/27\">",
"      Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009; 123:e752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/28\">",
"      Mericq MV, Eggers M, Avila A, et al. Near final height in pubertal growth hormone (GH)-deficient patients treated with GH alone or in combination with luteinizing hormone-releasing hormone analog: results of a prospective, randomized trial. J Clin Endocrinol Metab 2000; 85:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/29\">",
"      Saggese G, Federico G, Barsanti S, Fiore L. The effect of administering gonadotropin-releasing hormone agonist with recombinant-human growth hormone (GH) on the final height of girls with isolated GH deficiency: results from a controlled study. J Clin Endocrinol Metab 2001; 86:1900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/30\">",
"      Lee PA. Use of GnRH agonists in GH-deficient patients: arguments for and against. The case for GnRH agonists in GH-deficient patients. Pediatr Endocrinol Rev 2008; 5 Suppl 2:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/31\">",
"      Reiter EO. A brief review of the addition of gonadotropin-releasing hormone agonists (GnRH-Ag) to growth hormone (GH) treatment of children with idiopathic growth hormone deficiency: Previously published studies from America. Mol Cell Endocrinol 2006; 254-255:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/32\">",
"      Mauras N, Welch S, Rini A, Klein KO. An open label 12-month pilot trial on the effects of the aromatase inhibitor anastrozole in growth hormone (GH)-treated GH deficient adolescent boys. J Pediatr Endocrinol Metab 2004; 17:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/33\">",
"      Wickman S, Sipil&auml; I, Ankarberg-Lindgren C, et al. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet 2001; 357:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/34\">",
"      Kreher NC, Eugster EA, Shankar RR. The use of tamoxifen to improve height potential in short pubertal boys. Pediatrics 2005; 116:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/35\">",
"      Mauras N, Gonzalez de Pijem L, Hsiang HY, et al. Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years. J Clin Endocrinol Metab 2008; 93:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/36\">",
"      Matkovic V, Jelic T, Wardlaw GM, et al. Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis. Inference from a cross-sectional model. J Clin Invest 1994; 93:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/37\">",
"      Saggese G, Baroncelli GI, Bertelloni S, Barsanti S. The effect of long-term growth hormone (GH) treatment on bone mineral density in children with GH deficiency. Role of GH in the attainment of peak bone mass. J Clin Endocrinol Metab 1996; 81:3077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/38\">",
"      Bonjour JP, Theintz G, Buchs B, et al. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab 1991; 73:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/39\">",
"      de Boer H, Blok GJ, van Lingen A, et al. Consequences of childhood-onset growth hormone deficiency for adult bone mass. J Bone Miner Res 1994; 9:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/40\">",
"      Holmes SJ, Economou G, Whitehouse RW, et al. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 1994; 78:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/41\">",
"      Conway GS, Szarras-Czapnik M, Racz K, et al. Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency. Eur J Endocrinol 2009; 160:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/42\">",
"      Blethen SL, Allen DB, Graves D, et al. Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience. J Clin Endocrinol Metab 1996; 81:1704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/43\">",
"      Saenger P, Attie KM, DiMartino-Nardi J, et al. Metabolic consequences of 5-year growth hormone (GH) therapy in children treated with GH for idiopathic short stature. Genentech Collaborative Study Group. J Clin Endocrinol Metab 1998; 83:3115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/44\">",
"      Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. J Clin Endocrinol Metab 2001; 86:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/45\">",
"      Hintz RL. The prismatic case of Creutzfeldt-Jakob disease associated with pituitary growth hormone treatment. J Clin Endocrinol Metab 1995; 80:2298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/46\">",
"      Mills JL, Schonberger LB, Wysowski DK, et al. Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients. J Pediatr 2004; 144:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/47\">",
"      Youngster I, Rachmiel R, Pinhas-Hamiel O, et al. Treatment with recombinant human growth hormone during childhood is associated with increased intraocular pressure. J Pediatr 2012; 161:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/48\">",
"      Bourguignon JP, Pi&eacute;rard GE, Ernould C, et al. Effects of human growth hormone therapy on melanocytic naevi. Lancet 1993; 341:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/49\">",
"      Hansen TK, M&oslash;ller J, Thomsen K, et al. Effects of growth hormone on renal tubular handling of sodium in healthy humans. Am J Physiol Endocrinol Metab 2001; 281:E1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/50\">",
"      Cutfield WS, Wilton P, Bennmarker H, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 2000; 355:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/51\">",
"      Giovannucci E, Pollak M. Risk of cancer after growth-hormone treatment. Lancet 2002; 360:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/52\">",
"      Swerdlow AJ, Higgins CD, Adlard P, Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet 2002; 360:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/53\">",
"      Wilton P, Mattsson AF, Darendeliler F. Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database). J Pediatr 2010; 157:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/54\">",
"      Jenkins PJ, Mukherjee A, Shalet SM. Does growth hormone cause cancer? Clin Endocrinol (Oxf) 2006; 64:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/55\">",
"      Ross J, Czernichow P, Biller BM, et al. Growth hormone: health considerations beyond height gain. Pediatrics 2010; 125:e906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/56\">",
"      Banerjee I, Clayton PE. Growth hormone treatment and cancer risk. Endocrinol Metab Clin North Am 2007; 36:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/57\">",
"      Fradkin JE, Mills JL, Schonberger LB, et al. Risk of leukemia after treatment with pituitary growth hormone. JAMA 1993; 270:2829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/58\">",
"      Nishi Y, Tanaka T, Takano K, et al. Recent status in the occurrence of leukemia in growth hormone-treated patients in Japan. GH Treatment Study Committee of the Foundation for Growth Science, Japan. J Clin Endocrinol Metab 1999; 84:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/59\">",
"      Allen DB, Rundle AC, Graves DA, Blethen SL. Risk of leukemia in children treated with human growth hormone: review and reanalysis. J Pediatr 1997; 131:S32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/60\">",
"      Swerdlow AJ, Reddingius RE, Higgins CD, et al. Growth hormone treatment of children with brain tumors and risk of tumor recurrence. J Clin Endocrinol Metab 2000; 85:4444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/61\">",
"      Sklar CA, Mertens AC, Mitby P, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2002; 87:3136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/62\">",
"      Ergun-Longmire B, Mertens AC, Mitby P, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 2006; 91:3494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/63\">",
"      Wacharasindhu S, Cotterill AM, Camacho-H&uuml;bner C, et al. Normal growth hormone secretion in growth hormone insufficient children retested after completion of linear growth. Clin Endocrinol (Oxf) 1996; 45:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/64\">",
"      Tauber M, Moulin P, Pienkowski C, et al. Growth hormone (GH) retesting and auxological data in 131 GH-deficient patients after completion of treatment. J Clin Endocrinol Metab 1997; 82:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/65\">",
"      Zucchini S, Pirazzoli P, Baronio F, et al. Effect on adult height of pubertal growth hormone retesting and withdrawal of therapy in patients with previously diagnosed growth hormone deficiency. J Clin Endocrinol Metab 2006; 91:4271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/0/14345/abstract/66\">",
"      Ho KK, 2007 GH Deficiency Consensus Workshop Participants. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 2007; 157:695.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5843 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C7EAEF3114-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_0_14345=[""].join("\n");
var outline_f14_0_14345=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4131736\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSIOLOGIC ACTIONS OF GROWTH HORMONE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS OF GH DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREPARATIONS OF GROWTH HORMONE FOR THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DOSING AND MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H562846\">",
"      Dose adjustment based on IGF-I response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H562861\">",
"      Growth response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H562868\">",
"      Ongoing monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H562981\">",
"      Inadequate response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RESPONSE TO GROWTH HORMONE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4132357\">",
"      Linear growth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Puberty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bone mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DURATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      GROWTH HORMONE INSENSITIVITY SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4131736\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5843\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5843|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/25/13715\" title=\"figure 1\">",
"      Height velocity response to growth hormone treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/2/19489\" title=\"figure 2\">",
"      Height velocity response to growth hormone - NCGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5843|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/26/21931\" title=\"table 1\">",
"      Potential adverse effects of GH therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40040?source=related_link\">",
"      Calcium requirements in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=related_link\">",
"      Causes of short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/8/134?source=related_link\">",
"      Clinical features, diagnosis, and treatment of Prader-Willi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/5/82?source=related_link\">",
"      Diagnosis of growth hormone deficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18376?source=related_link\">",
"      Diagnostic approach to short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1833?source=related_link\">",
"      Growth hormone deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39270?source=related_link\">",
"      Growth hormone insensitivity syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/37/3672?source=related_link\">",
"      Growth hormone treatment for children born small for gestational age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18248?source=related_link\">",
"      Growth hormone treatment for idiopathic short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27881?source=related_link\">",
"      Growth hormone treatment in children with chronic kidney disease and postrenal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15769?source=related_link\">",
"      Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14329?source=related_link\">",
"      Management of Turner syndrome (gonadal dysgenesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/12/3266?source=related_link\">",
"      Patient information: My child is short (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/7/3192?source=related_link\">",
"      Physiology of insulin-like growth factor I",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_0_14346="Advanced case 14 with answer";
var content_f14_0_14346=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Duchenne's muscular dystrophy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Classic findings in Duchenne's muscular dystrophy include resting sinus tachycardia, deep infero- lateral Q waves, and a tall R in lead V1 due to the underlying cardiomyopathy which is often associated with posterobasal fibrosis of the left ventricle. Left atrial enlargement, as indicated by the prominent negative P wave in lead V1, and marked right axis deviation are also present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_0_14346=[""].join("\n");
var outline_f14_0_14346=null;
var title_f14_0_14347="Management of myxedema coma";
var content_f14_0_14347=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F61507&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F61507&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of myxedema coma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Draw serum for T4, TSH, and cortisol.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Administer thyroxine 200 to 400 &micro;g (0.2 to 0.4 mg)",
"intravenously followed by daily doses of 50 to 100 &micro;g, and",
"triiodothyronine 5 to 20 &micro;g intravenously followed by 2.5 to",
"10 &micro;g every 8 hours.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Change to an equivalent oral dose of thyroxine when the patient can",
"tolerate oral medications. (Oral dose = intravenous dose &divide; 0.75).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Supportive measures:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mechanical ventilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fluids",
"and vasopressor drugs to correct hypotension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Passive rewarming",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Intravenous dextrose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Stress-doses glucocorticoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Consider empirical",
"antibiotic treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Monitor for arrhythmias and treat when indicated",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_0_14347=[""].join("\n");
var outline_f14_0_14347=null;
var title_f14_0_14348="Guidelines for liver transplantation in HCC from the EASL EORTC";
var content_f14_0_14348=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F83729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F83729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for liver transplantation in HCC from the European Association for the Study of the Liver and European Organisation for Research and Treatment of Cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Liver transplantation is considered to be the first-line treatment option for patients with single tumors less than 5 cm or &le;3 nodules &le;3 cm (Milan criteria) not suitable for resection",
"        </p>",
"        <strong>",
"         (evidence 2A; recommendation 1A)",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Perioperative mortality and one-year mortality are expected to be approximately 3 percent and &le;10 percent, respectively",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Extension of tumor limit criteria for liver transplantation for HCC has not been established. Modest expansion of Milan criteria applying the \"up-to-seven\" in patients without microvascular invasion achieves competitive outcomes, and thus this indication requires prospective validation",
"        </p>",
"        <strong>",
"         (evidence 2B; recommendation 2B",
"        </strong>",
"        )",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Neoadjuvant treatment can be considered for locoregional therapies if the waiting list exceeds six months due to good cost-effectiveness data and tumor response rates, even though impact on long-term outcome is uncertain",
"        </p>",
"        <strong>",
"         (evidence 2D; recommendation 2B)",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Down-staging policies for HCCs exceeding conventional criteria cannot be recommended and should be explored in the context of prospective studies aimed at survival and disease progression end-points",
"        </p>",
"        <p>",
"         <strong>",
"          (evidence 2D; recommendation 2C)",
"         </strong>",
"        </p>",
"        Assessment of downstaging should follow modified RECIST criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Living donor liver transplantation is an alternative option in patients with a waiting list exceeding six to seven months, and offers a suitable setting to explore extended indications within research programs",
"        </p>",
"        <strong>",
"         (evidence 2A; recommendation 2B)",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HCC: hepatocellular carcinoma.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2012; 56:908. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_0_14348=[""].join("\n");
var outline_f14_0_14348=null;
var title_f14_0_14349="Sensitivity of CTA for intracranial aneurysm";
var content_f14_0_14349=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F81565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F81565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Sensitivity of CTA for intracranial aneurysms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 306px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The graph shows the increasing sensitivity of CTA with increasing aneurysm size. Points represent the median, and error bars represent the 95 percent confidence limits. Aneurysms greater than 10 mm have been pooled.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: van Gelder, JM. Computed tomographic angiography for detecting cerebral aneurysms: implications of aneurysm size distribution for the sensitivity, specificity, and likelihood ratios. Neurosurgery 2003; 53:597.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_0_14349=[""].join("\n");
var outline_f14_0_14349=null;
var title_f14_0_14350="Fatty diarrhea child";
var content_f14_0_14350=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Algorithm for evaluation of a child with fatty diarrhea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 290px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This algorithm shows a typical diagnostic pathway for many patients in this age group. Other sequences of testing may be appropriate in some cases.",
"    <div class=\"footnotes\">",
"     IgA: immunoglobulin A; CT: computerized tomography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_0_14350=[""].join("\n");
var outline_f14_0_14350=null;
var title_f14_0_14351="Typical sleep time in children by age group";
var content_f14_0_14351=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Average sleep time for children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 492px; background-image: url(data:image/gif;base64,R0lGODlh8AHsAcQAAP///1e23QAAAP//AMzMzP8AALu7u4iIiO7u7kRERN3d3SIiIhERETMzM3d3d5mZmWZmZlVVVaqqqj8/PxUtN39/f7+/vz8/AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADwAewBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChcAQNAgIQIgYMAgsEoq+wew8OAAQCrgwHAA4Nsb6/dQi3tggABgLAycpsCbTHqQIKJBam1dbX2Nna29zd3t/g4eLj5OXm5+jp6uvs7e7vyEsIDai1AsXPLfHL/P0j+0hUPSCRa1cvff4S8gN4BII1VKpYuUKosOIvhmAwWtzoSaMXjxxDYgLJhaTIk5JM/2pRibIlI5ZYYLqcaUimFZs0cwLCSYWnzp96fEoRCrQoHaJQkBpd6kapE6dMo6KByoSq1KtirCrRirVryTJct8IbS7as2bNo06ol+yLsEbdI4Hq92BbsGblzY8nEO4QvEb95Q+21awZw4E+DyRgOsvgwp8RjGv+Q7FhPvhQCDMCAnPVu5TPHTC3QTOUyisyb6yr2/LnMMWm8qpg+gVo1xcisW495DSBCBGMLTA00EFzAAQWlBNA6ULxBcgkAEhSXLoCBtAOiXQlIPrw4MuSmUIE3RdoF5zCUe6TXnSO0gATSGAyUwABAQRG+azEwwFyBAuMAQJBAdAM+gNoCBxDAgP8rDvwGIHP26fJMBOItGMGAANRmnm2dFcbebtE8YN1/1vwnjQgLDBTdAwdgiFqL0UkYTwIHGFjNAhlq9sACJhqDjHcC7KiihrexsF4OR+oAEDdZ0MgDkzYQOQSMrkVjEALyEaQLfr/Zwp+LmsHoZD40KjiRCKjtGCEA2PVWD5f2lFfkCkneUCcOSw6g5556YkSiKbS04GSOOQyqZACIJoooRscsUIyAhJpAJJWDGmoDlWTwRiBxohmzinHjLQcmmwOOOaMu2IVHqJo2lgLAeNEQEFwpchrJIXq5Zcgnn35aaUADv7FgaaFbHqpoooyyggqkmMlJabE6YJrTeRnlKsD/rnv2eiIxDgn3n2bHpBpkZo1WFwGgryb3JgAIJGBKfU6m2gqb2WXInQoCHIusCccYaACkqJ1rii7beZvNA06yEp4pBwncQDEjOFANATByGiRwwtmbsQoFdNxxCR5/TELIBYAc8k63VuvhP9j2aUKPaJYHQS8QLIvKoOQeWCAyFL664AjHQByjmbtEQHSDGaJaH2b6LspvNNIBzJ91MSbNJo7PipCwLhDw+O0BDwPQALQCQCcCjFnSZ9989T24dAokm+yx3CKPEPcf1H5xp50kXNuytiIQc8CnOKrSI84GkCkjAECqKILEBdFoo2iTs0KoprQ1HUCyCtjyXo41a02w/45YY1jp6KTG3K2qIzB3CgIt/mmK7NGghrkyeX9kbcsDAP4rBP9B5wCO0QGrdaA5i+6jmyrYokCZPwcefcy7EH+a5pwH+HlmzCGAAIKrYn1QM8q/CCbYQp8gH9qOr923ZsNnMVsTvKQvA9iSpqz37n+/bM2W7mIF8SRQGxv5S3HLg9WJfKSqeFUDFeJCxY1qVYJ8NS17/xlQZuYhGtSpSUGnMGDCwjQqgV1MBFhiGOwGZLHCFQdHE5SfUk5HAwVQrRbJQZDsAkUvU0RAGsPKXRdUMoFrTKAnfeMdUaTVBCld74Iz+F77quBEK8wvBsOaAQQCZcN6HOCHvjLe8FzxPP/NSMB6aNKfERyAoR5maU74usKStlFDBpjtCVWUFB03Y4o2ypGCUSCFD58xHvGo62qrCJsIJocwghWnWw1TIQkWYDb8kQBmxLCjCYRxpgyp8S+fY1fZqrehUlLxQ2Kw5PJ6ZkMCsHJB3fsetGgIoK75h3thG1vfTnSAdb3KSjEDZglG07dPEgFTC4gA7IJlK1MiEZVgUMC5GvCAZzSucZRaFy1JqLqH7PJsaPzltu7xxmHKSYjHbCPYpHNObhDgnfCMpzyHIc962vOe+MznPfcGzfuNhmfr6lnrBmTD9pGvauaLGfpOQEkR2DBYX+zR76qnmTKKspP01KctmkAlYvj/yH6nMWYT+/kFcVXzO8mJhgLFxcxFCmeEqSOUCdu3RaAlZ2yyK9bqgAeAM1ZQpELo6CgNBFLaAHUJ/CQpEJjYAxsusAZBPOpkqnGdd00RM1JNQlKV6gOm9qB+lzpIMZ2JK7IOhasiQecW1FoVtIaErVmA61bcyhG5yjGrcaHrRux6E7y+Ra8W4espzRqFtRj2sIhNrGIXu1i/PhOOgI2sDLYaA8ECoIjWOKJk3UrZ1BD2s5vtZ2ezSpTRhhYYpoVsSGmQ2tPqhTCqja1r2dNaOjn2H7NFa23jCNpm5paku8Vqb237W+DC1reTLa5xVzNc3ioXlcFdrWyJ+9wPRdeo/80VbnVpe1zqJne73GXudJ0L3s9cN3/ZlW55K3Pen6YXu+tlb3fJW9n4mne+2v2ufQ/T3rGON78uwGw1NLvfuuJXvfVlbYFR0l/cvhe9M2jwgo9yYPjq98ITDmyFIYxhz2Z4rxt2b4RrIOEPw6HElnXwiE2sYfEiN8ErZrFCjsRGEnQLWvTN8W3TKOMZVyWUAZoXaUlM5B4n5EhUEgYgdYxgD3fYyMlAMoaO8SmyuVOj78woluOp5S1n2ctgDrOYx0zmMpv5zGhOs5rXzOY2u3meHMXQRnsqTCZbGMZPXoGATUFgKKckziNI2z3+y+MY55nQfk7EekqEsXJ699FOxv+zpBMdCRTv2JMKzjSlJ2HpB4v40C/e9CM6jWgOT/rSovYDqUN96dLOYM8C6HOqKexiSLe6yJqe9R1WbWtP+xfUrNa1HHht52CX+tPAFnYbiA3gSDsb1SVWdrLjeutcnxrV0lYZbnyt4mk3+dnZbkqIf33tY5O73CiAtazDfddaF7vX5u62t03Nbmq7u9nVNvS8kV3vmIxb3uCOd6H1je1+F4HZ3+b2wNFtbHgb/Kz3TrjAMU3wgDv84Un598ItfvF3d1ziGM94xO/McY/je8fRTjXCSZ7vfdNb4SH/i8Yp7vJzQ9vaMYf4tifuapyXHOQ5b+vIXw7znvvc3OoO+pP/Zm70mgP85yyHudJPPsSWM9zkVP840KfudJ03XOtRnzjNoR52rldcd0XHddc3nnazK4npar961r8+d6y7ne725nncyV52uxP97nL3d9vPLnahNB3wR686bb5hdb7/HeyPR7zY8XgabPktW42/OeHxLvm6572Clt9VitkudcPvvfMFHyltQs+rzJc+8ZxHfeSFUGMSYGfJRPcbyXZ1N7udbB+9F0HvkTE3x/N78LI3vpKADAAb4f74uhrA7vkUfADEDfgnG1nIruGxarx+85BPPumLgCn6EPD5No8+r0Qv1ctnS08dc1nhYR9+8UsZGgb4Vt+uXE/390n0XtZl+8R6//HXO1smgAFIZgiIZQv4Zg74gBAYgRI4gW52f9pjDehHev7XO+y3eN5QeaJned+3dim3XRY4AvqnWhvofx6xgh0oKazXevMHfn4nfmP3FlSFgnmUezEofzAYgjL4g+v3gvWXfrE3ezZohF+xekCIeUw4hE4ohO9HhDUIfUdohUmIhIInhf8XhKDXhD74hVAYhUX4dHqXhZP3FCA4hr2zhlNIhkkEhAUIE0hhevSHhuO3hFzIgV4Yh2zYggRYAGH4D+CAcqeHh1gIA95TVIzhhl0IhywDhm34hFM4h5T4iJDoeX1XhcmnFAjAC9WgSwfniHyYier3hoMYiUNoiXu4gv+GeId4iBSDwzDOUS99QYosiItUqIqVKIiTKIaomIqaqIWbGIs1IAwIIjQK4AAMIFaNeImlKIyniIm/CIzUWI28eI2jd3iISIybBAFFpQC+NBm62IfZGI3YeI6u2IoiqHDc2I1K+AIQIwGMSI7QmIv3uIto0oPC6IL6mCGMd4bwWIwrMDjPUx1PJQSAKIkL+YflaI7TiI7puI8MiXwDGY8tACy2sAAMMI5A0JDBCJLUKJISqRH+CJERiY9XiJHGeAMN4AAGcgCxMYr5iJInKY3+yIrWWJIP2Y+FmIaA5xQRsADuIgEzKXM1aYo3OZEpCX++aJL8yJRLCZWSyJTeaIP/TkFAlkMPRkCSKrmTX+mHvdiPUemV+riUVpmIiAgVRukfDtBJCtmTUsmPZil9T5mUSkmXeCmNV2l/OKAAd5RXe1mXeSmHd8mO/ziVe5mWLImGToEd9fiMiFmYDrmYVMmGc1mRk2mKV5l0d+cUTrWIfzWYckmYmYiWpjmRqOmOnecUEmMNPHSLpDmbm0mWVZmalxmMjGmGK1lvrnkNsRmXtAmWiVmWllmax6lHAVmG4QYVi+g9o1mbuCmXqmmcw6mO7Uic/6iWMfebsNmVyHmd2GmXtomZ01mb1XmbQKlr3lkNwSmZ2kmZIVmOOimW2hie8Xma1smc2eaci9hQNCmd//ipnfU5njapl+iZm/fZm54pav6JAApAlOApnhRZmYhZoBWqm+eZn+WpoTPInjjwmtXgR8IpoBTalOSZnuY5oAaqn+rZm7zpZ+0pERNqojbKoSrqoRS6mgn6obP2oJHpAxvKoamZowt6oy3aoUfKiTEKZVYRpCZQe7tgi8GmmCfKozg6pElqpDwJo3mYbkZUXlDhOuCjD0BmNL3RUkxmpUi6pQrapW2KohCJpUz6pXVKV495DVeFAkyFNCqIoHEqp9U3fRxIMgBBqE7pMfJnqNQXMnO6n3f6js/lFAnQAASAAKRAoinARIazf9swgAwJqn8oqm9IMvJEqNdiqPGEqP92qagGSACMuieIKoCoyYBm1oD6hKsUuKu82qu+6hRcKQIz4wLSsiNwuaaASqTU+abrGKd06qY+Gnin5RQOEQENcgrE2kaVCqXpx6bKmpxZyqIZuqTQ6qU3mHpK5RTfcyPcWiK0k5AJ5632iY5FyqzZ+a3h2qPmKqnK5ZwyeQDc+nZXmqzz2qwFe68H+6iGqaRwGqmHqAINCk1U8ZzRia8W64cXcA0X4KIruqOByLAGO4wEObJ9ORdOISvfGaAXm6Qt+JP56qwfy6Uhu3V1yq/hZQMB5J41urLjSq9PpDn7oq8wu7Ayi7A0K7LcebSOQak8Ipo7m7DyOZI/C7Sb44H/H+ixRGuv29mYSluydnpfx4gAZ0SxT8uy4oomVBu0FaQvFqQoWtqzMyunnMm1JJu0dZsXRCEM2fCeH3m2ciuVaes0ksK2bHsaywm1HKuj/Gmz/HkVeasNfGuPgSqv/xC4VTu4x9K2aru2mZu54Iq4fEm3XnuuUue4NvCcZKuyoPu2aBu4Jkm4nps5neu2n1uui/uwKxmxQIFwlAu3iWm5rzu7tCu7bhu7FeSyoLubpGuRyve1LpG34HgC4oiUk0uwleu6xIsshZu9i2K8fQO7HSO4L+uwsNi1dstgx8gKAIuCzOiMfTuwmom5aRu8xeu93yu84nu/9Ru+lzu+SHu+/wAsugL8VpfyKc6RQ8cqpH7buxkCvMRLAddAAZurv9o7vJy7vwWQv7ZLvjT4v01KE54IitUhitTLswB5tfJLtfSrwlPbvRZMwS7MvyaJvB78wTW8vOZaERMbsDvAug2Mv/17wSycwkDbgrA7wa2LwRqcxBX8wjeMw8zJuCegu1F2YAysuS6MxExcxNyLPS28Ofa7xWAcxj9cv06MJocbxbirxj4WcVd8xEssxlBExF7cxVi8wlmsxVg8xmdcxnkcx+Y7wM57tzYMC7ybxtdrxoC8x3MsxFxsx2S8x5IMyZEMxEHMxh0cyIX8CrwLx5ecyE28yA5Mx43syHwcx5K8vf+mPMlEzMoCSYJr7AtQgTCWSk1lK8Z3/MW53MWlDMqPLL8QbA0S/MllHMzVQAGDGjLaa6ja5zFuSzL9a6g0fMNSjLRUzGk4MDntoqbwCcOnTMx+/MdGjL2krMqmbM6+fCzJ7Mzdy8y+x86LAs3Y132eDM6jW82aDMWVhgPOAZlHKZt0vMsBTcbhXMfnjM7pjNAF3cu4rNB3rNA/LMMQfc+xXMMl+Fg18JIEhAAR4L7dnM4CvcoEzcgOPcrl3MckXcmWjMeuzLkSTdAUXb6ErM+QQK0M4C7ngmMf3dB9XNAh7c0MvdAQndJ6bNL6a8ymMMzE/NAjjSgvjdLTnM80nc//Fz0F6ppSilTC3vzTIN3U5HzQXj3EYI3SRu3LLX2/T13UK828r6gJ/uoA63vLPh3WoQzORK3W8/vFJf3VQL3XdW3XTp3B37zU9UyHFU3Vj6EDqavViYzUAjDM4xwAjg3Zeu3XYj3WqFzWcmzZgx3Zf43Hnc3WrLkJJwskkavAvEzXBo3Zmc3XfU3Wrr3ZKv3ZuszZof3K0hrA18wHlAqccn3XgJ3XqT3bl/3aeF3csg3btE3Jyr3cXorPMU0IlNoACuC0qpvQqh3UQk3cv8zaoB3UwE3YiizKaz3QkRzVMz3V0f0Cuz1zKTC21s3YyU3eyD3frS3cJ33c3Y3d3H3W/13N3bct0jAdwJtM4IM8umuFAyCks9dt35692sat3xDO3xIO3podzv7duml938691RNt4OoN4tBdVjjr2w2+3VqM4vRd3+H94BYe2yrO4QHu0oKd4akM4Bme3naYyemd4DdQqdUNnb8N4zHu4i+O39493M2931uc4xa04eI93lHe4TUr0+vNBlnpKPEN0Emu5CvO5DEe3Cx+4S3OvU4e2H885WkO2jaO3l474iDu4zYgoujSAlIaEUJWpUQO3EZu29rN514u4xOO4UON5jP+30t+6Dzd029+2D2+EiFq4nQCZAXxz2u655gO42Ue6N/t55x95uUt4Ilu44U92jyO4P+QfowotNgFKWeDdkVRB+icXtkA/ueaTua4LuUuDs2Xa6iKwuvxnH1Prsy/nn1oIs+Jss51Q3x1g9vNq4cyIAwOQOfKka3QAA0L1A375LrbPr/d7u39B7zfXsT21OLlLu7hruvjHtjsPAy+nuzEHuwek2Xszr/wPu/wJADIXu8FcKohk++w2jFgpqv4RPD75KsU+LjTLumtHjivbtizHvH5XeGFjuQUTvH9XfG6ztwSTuqhTlzN/tyOPgLtrYaqzi6srgKYUukeHa+ZXt9h3unZ7em1/ukaT+WL3vG23eba0DHeJ/JWHufyHQO9FDGn7am+sgp53muyPvFiPuYvD+b/m87aag7qG2/eo77zWj/gBS7iIz9Xp1s/3jOsJ970Xe70aj7oRR7oaX/ka17bOL71WR/3XH/gXh/0WmUDWnkNmvq+Tt/nPT31Ef7lbi/1uY7zOS/oHn/1oq7zdR/id3/qYE8De38jCSy5Z5/5g9/2Nz/ogn/xMm71iH/jc1/6js/oggz5qc8TJc83p9tLW87lgw/4Kf759v30nn/4UI/4c033pq/4cp/ikQ/LeL92Ivf3tF77ug/ma4/2Mr/kov/2WH/61A/8ASDDVgslQC/5qY+uSJX8hN/5uR/142/xt8/S4r/4o1/q02/92N/KH776X9/9pWvyyC/xVP/8ym/+/zEPAoA4AkJwoikqkKOZvnDrqkG8zmV9n+zM23Y5IHG4OxUKPSNMmPs9oySfNEqtDrHa6nXr/YJdT6DzVyu3yGjaWdVlt5fmOG5OtzFXa7jene/L2AHWpR35CfYgKeEhFmm9eUFuST6GhVGCGUgQWHaWjN0xIp5Jqh0Whpam/sVBmgaiDsqNOsbKik4Zwua67en0BiTN8t5iTnkaSyVbeUY2ixAsCEwnIDw7s5KC3qmujmpn+74SEtO5nlBMq1OQE6erC7APw72vt4sQieve/zadlgf5pwwZwU7Lnh2UkkDAggYMBDi4NmmbOYqtLF785qtfRlsdAbY5xw1jyHD6gP/t4pNIIL5981r6S+kCHk14Ew0W/DKB5gQu1xI0EIGgocRKJmXCrHgU6biXST+qLKmRJUepU5mGwhW1FkiuW08Ww+iVGc6ylg4mjCJhAYK2DSBYKzpwqdOq4K7ya6o1KlilHq2C3KhX5EhafVdiRZlXcV0eY8fkvBR5bjMHNQUElQuZ7t6ngAMf/syX6mDOnZt2K/z3btfQj/ORZty56uMsZiXfpuzJcs3MmqFwTg11dGxveE9nJewXNFK7rIknjrlYtvKVwpBLb0z95tnJX9BKbCu+7e/Nx4WL9py+dHDT1dcbXx36edJ60+RhD2A/3nR/16vX5thGwHWX23fcNfP/AFAENPBAeebJ1xxqJNHnnGDxQdffchnOxl6E0W2oXoWw/cdKgNsZVaCKuGGR1hMPqINAAhE8aNt5FFJlYXGqfeiUh8yBmJ6OQcKHoYiuKeIjio2Ic9llCILh4jEpetJAAwcIgIADvtUoRntfHpdfiEcSOWJyYPaopJFDajicXS+UyGSOAu4YFpVRegdhJw04IEGWEXDZ5SdoAqndmj8WKqabiJLJD5tq8sihokVmp+iJlb5XG4EscqpbJxAwsFAEAhwg6JQ3EirpexU+uup8r0p4Zpiu1rmoS5ZeiGk2mqaRJ5RkNYNAA+o0EJepg6KabJqTsjrhrO6l2miblI7J/+ibh11q51+8ntrpgXd2gsABDhxg7LHoNbvmo8zmWq2sy9LqqLXzvpvopK8t6RG++Xr67Yr9WqJgAww6eCyyaaLbrrvqOgsvtMraG++0Zh56K4AKB0Qkt17+669Pz8A4jYw0GpzwnAzXqyqOZcLKcqwVwxyptJDuF6e+GO+rK7jYdKynJVZiqWWgXZr88pjrSmzowjIjHW3Tz0Lt8FQ2A5QtYtO+5mRNv/L8cTN8+okAoAYfnGjR8qY8c4cxL922kPSybWvcKVCtktUZY41kjpviuTMYoIpKKtlnK+3m01JDrHbS7BrtNrVyM21K3Z7dnbO2re3dq4E+hyEsseYKSv/42kwfHvHKE7eMeuOQO05x5HFMThvOems8oOY92xjsuOWSXTaHoovO+Oqut5766K/PTTzrrSTRPEzNJ8GfIs67AH0BN1jfgvXWQa899DBsT0X2JIw/QvkinA9A+VKSMN54vQN/euHLv5288cLP/7j+yu+/w/hwfo9u3ase9LA3QPMFEIDUQ2DzwPc98R0QfRFU3wTTtz5PIMBJESmZ/I5nOLiRrmGmi5rZOog/SBWvVv1bneWuhkIXnkZrNuFa7sCQwcts8FwdjN/DEIewHo7wh0BUGQmJ6MPfiYV2eVOhY7oGMC+4Tzzw2yEVh6i4Kh7xionTYhZLZ8QgltBESnz/Id7I2EQa8i1cIpAA6LyAJQEwoGAtwqIQi8jFOoLxi0i0ohfvqEc/zgw9LSzjvcaYEPA84wAMUMBCFtk5AUgAAA5YAA1FGEY79jGQfAThB9OWSU7Sj3+zY+IYC9mcGgKrShEgAEMYAAFLLCAC4iLZHJ1myT9mslWb9OQtAflJXgLTfi/bD34yVUpjnjKNnAMDn2A0rqFp4QANSMACDDAFGRIgm9rMJmq2uc1uepObyQknK8dJTnB6czDnNGc6U0HOcroznOqUJzu/WU9tzrOd3HgnOu1JnXX+k56MEcA7z1nQdF4jAgtYiAS2FAZWWsMAWfJbL3W5S5QhL6MpRJsw/13mUdV91IP6GyRJM3c7r3nCTwwBwFseCkkAwKiNqNSkLYMZwo6CNKciXWFIT+jTpPFwW8fc1d5kqI5lgqGhClCAAzgRhjfGsZIYPRoo66fRUBoveIvb6kWvmi6vlpSUp6STvHpXnqDiMY++tGgXq4oxnur0p13tJFiHapixDhSpZt0cW9OKS2v19a82patXRXk/rm4xsOoJa+3wmp1S7FUzaL1kWz2p2F/idKeGVeFmewpUOn5FrI11lOwkVJT3DQ60e8QkYHvp1qyaELGVzewJJ7tYuwrVsbKA7DOiAY8cmsq2NGWtZV07WKwOr7Nxla1aL3tZ2Ix2iaQla2N+Qv8T4IZOtcOd7U0Le9ia0pa5gs2scKEr3fPOprRlfQY1FSDF1IKXqse16kaXG9/6klG5+YVttGJATPSacrp5nWlS2fJeDt6XvvjVLGe/m9jXNjjCnk2wfgOMXkpQt0PX4I06sEs07ToXwsmVsH0fPN8Ki9eXFTXu3BhbF/VW9xkcnoaHayTcEJ/4rQ7mLmEXnGLMenfEE75rdNObYd4+w31TpLCOd+xXIONXq3NF7pCf/Nz5utjIA1ZmZPm64qn6WLsi1qmUiRveKX81zHb4rxmLuuWTemJcDphzJBFs4u4GWcgl5rGCqbzn5o6ZwVUGtEsw/OZudeKNHYbvneV75v7/5pjEgh70ePNMZjFHusiGfqxet5CAUC1gknIMLoi//OgtBrq2sUUzill9MkvvV7QvPnKntcCnA1Byzoy2sqlhPelYU3q7hD71sGFd3kxf2AqH5liVIOAnCFhp15SddqUdrWY+p/naxdb2ap+camQKmNME/sIkh0JjaXeb2iouLrGr3We4AvvP7s42vOVK5FkvGx/hAQBTS4VuYad73vRutZmtze11txvgCv92Hti86d3WWgsCI9i/cYzngy8c2fH+9cbtjW39HjvhzoWxhkEWoxlVvNc99nP+nCzwV/v6xwxvNMs9rm7KzekaQMuSQ+3MazDXPOQxZ7LLET50mtdb/+bqIjmSq9SnP0HzQTdWedAxLXKqJ93VklY1pK++dFqP2wuAE8Co/K1DoutZ3gGHMsvL/PGis33gcA/0w13Y9HANaxrFSjnQ5Q73K3v94lUvOMaxPneN172Mdw/X7mRq41L3neCo1jjXCT/4t0ta6IX/OjpoIo/Ff6Ghcx59n/gueL9vXfOXv/nMMR9si2+evMqmamVwaHqDv1vy3qb8Z7X++tazPvDGnv0Ha48Z0tf57EhH/esBf/SfCz/2w+/682/OJtB/4QALWQDvlrz8Jqfe6tVfe9x1//LMi1/6hrt+xLEggYfU+MNo5+j41w588t/f6OrPffgtzyr2h90W4P8aQ4ya8kEf7mUd9e0f86ld+R3e6T3g9NEF9m3BA0jDlRyYAQYfBP4di9Uf7C2g+ekf//0e4hHf2xjfdd3eyjFgx6leAh5gCEZglKXf6pEfAHLZFszYovncBiKgCGZc9JFgCQohvL0gEFYUDsJZ50SRJ0DANJgdSvkgCwKh88lg2rmg7zWg4fWf6+Eb7XXZDEDAAjiVVHEgFtqcuuUfCNrgCMLgFL7h+YVb8YVh+wiANXkMHLZgGtof783fFvqh/4EfIMqe/FCgWUnUQwjOTGgNP8WTQJmDIz6iP+0TQEUiJF6iPlWiJraCJG4iJWYiKHYiJo4iJ5aiKJKCJ54iPt3/kzhNIit+oinuAD/VIQmw0hoJgAJQVOTBHMZZYRuyYRy6IRLyIhFKIF4collFVdjs4hnSny964BU+IzCuId3VoDCO3DgkY+8YgDREVTP+YC8C4y9iIxd24bZRYzES4jH2yDbWohTinzo2IDkSozOuozRemgKmI+koIaK9Y998nzhiIz3O4BDe4z6yYx8W4YBoY/v9I4GZ4zQOZDQiJBUWZDmaoD5iJD82ZAA+ZCrp4SDOI0VuZDieoxweZAsqXSFOoEN+pD8qXDBWIUnWo0kaIz5u3BFeJEOG0Et6S0xG5EguJH8J4k4aJRauZEJmiDv6JEzKpEDO5FCinxZmYVFO/+XkSeUcomBTOlE82mNVYuUHBiVYomNJWuRNtt0JNgtXdiVQyiNZqmEgxmBF0qURXmNNrl9H5iBbLqFbfiUfBqFYviVgVmNGhiVOJp5g8CU4nqVERqVgsqQXwuUwEuXuZeUX0uFiPtFYul1zEeRJ+iVkiiYNaiReCkk/MptmQuRbdiYufSZa7mFS4mTlWeZonqZe9qVqpqZX2qRQ2qZdUiVhymVIgqYD6tZW6uZqfmVrrhVNHqVjPmdKgtxdRqeWgWFychlnrhomvaZ0QmV1CmdkxuVlWmdmYqdTamdw6mRxjmV4/uZ0lmZ1JmbOnWdupqdVIqV6/uFkGidsiqR7kv9mS3rkYk7dYP5Yd/Jne8pmXcLnYTKom11nferbfjJnLjknexqofuJnPjqoWd5mT0roboZmY/rmbPbehibocPLmg14lMrpkUxboXx7ohfrnd2IoedLmeL4nhJqnhMZob/InggKoQaYojp5obSKmWipmiE5oQKLhjBrpfg6phwJnh5rm/+GmUybnj5JokNKodz6phkpmjirkjh7nWjKp74wokQKmkC5obIppWTYokrKoVqIpk3Ipm0KpmYZUhRYmea5njZ7pkuIp5MkoH7kpVfqpilJmi+pokhrii/pknsIpd35pkQLplF7pnD5qnWImcoYopf5nm16qptqooKIqh9L/KZXyZIT6qKFm6p6aqJS+6aZWZqeyKo+C6qtS6HZ2UaKi6KJGabBS540eDWo2aajCapeS6rDOZa4aa4Cuqq0OKn0Waq/GKa5SK3RGq6fmZLGmannuan2K6qmWqLeSaaOGq6nmJ4qmq7QwJdlgCR7WkpNya/OVaq2aK6bOqr3ya1pG6oCSTcjQKzyuaaX+ar4qqq/KKXgeqbbKp5Ja6zu+n58U7GayJsO6psISa7aqK5je679WqYsKrKlIlAEowB1eUyNa4irCYiiiYiqSYkioIs3OrMzKIs7GrBvUrM3m7CzeLND+LM8GLdEO7Qr0rNDurNEuLQy0rM8WbQ/Q4j8+/yE8XOwy3eeYBirItpzDeuxTruvDFkq8GkzKXi3WZuzXAqtkCiufci3H6aujjq2kCorZmiGQti3efq2C7i2jgu3bviuyqil2lmuYWqqzEme3QmufguvbzqdppWnhhqyXIu6KomvcMm58Km6r9ii5LqueIirHsq3GfqzIcmqZQqqA7qVqSm7XFufaNqzham3fLiftHmuWiijhfi7Ceqboxu7ksmvYYuvsJpbgss9Hti7HNavbfqvt9uuzem3x4m6y8qq/Kq+sXi6tOq+3bq3p6uqdKuvwEq+VRuz2Lq6qQuzmfi+hhq/15m2XYi76oqT3qm+7jq/1Te/gbunujir2nv9v87pr/NLv5Apw4Obv8T5k8r4vkRaw2JZu8Dpu4w7wp4Jv9ULvvi7v8yau8Aaw+M6vAYPotbov6Vpo5R7stgKuA8Pu/D7ueonwBctu75rw36aw+f5nAzuN8abp4Gbt7xKwDWMwDnfwCA+xlelw5PJvEIfuDPNtEfswAE9r+apubu6vB39w90Lw9QJx/f6wE9/gAe+wApNwazFxhnrxA6uw77KwxELuC2+w6+JrGR/qGfen/AZm6pLs6mqmGKutGpfuAqPwBMPtFtsp+1rwG2vx4TLvu/7pIqexHN9uCLcvDAOv/wYyI/ttI0tr+oZrC8eYG1su724sJDOrEN9vKEf/rxGDMRJbMRpLcBYDcio/MRYLsCeXHCifsBIrsgajsixfcStr8oe6que2ch3DsSBjMilz7yvXMhu78CQjcizvqykjchZb8yM7cg6vMi7TcCInrDKLsivTcQ+LsypL8iH3cgyPcjZb7zUT8jG7s/SeMzETMR2v8B+PcSbrc+2OM+cN83nysT37sTFLMwePruZ2sjN/MjSncyUvMTtTcg33Mz+fckweMTeTczlHMRfDczxXdDdT8xfPM0AnsTo3Jzj37zsLMi0vbMDqMdnwBhneLfzmc9p+dBPf9D7r7URH8j932SoBQATQksGCdE1T9BMnM0QjNTbzskVv80c6wFBj/+xRLzUztzRPN3VRY7Uwd24tGoAjMaKTJC3TNq3UPi3UvizMpjVau2IstrVawxNcxzVc51NZm/XRIm3U5jVe28BYO61e37Vd9zVgE5RfB/Y3vaQFlmG9RrQ3y7BSN7RE5zRVa7RI+3RkAYXjoS1lVzbqLrNKe3Q0q7Qtk22XpCw86CJji3Yfo7QuTzbzsnTHTrGW6mZAf/Q9E7RRZ7U1InQEuzQV13ZJO/QuZ287h3Rna/Vr5+VI624xryFu8/ZW/29SF7c5X3ZwO7ffQrdhKnd1r3Z3YylzV3E93/ZARzd4XzJTe7dld3Vzk3dV9/ZK6/Z643N8w7JC3zJD57JJl/8wZO+3QcN3Yx93Noo3dr/3L9t3M4P2gGd0MIf3dbOucHe0Jfvyf0t2gH83hrP3uJJ0dovcdosngqP3rXr2/5I23SKvhDv2Ou+2GY84Rw+ydHMuh7u3gM83A4/2jaf3VW90Qv82bUe4h38giCulMYf2Gic4j7cjiiewihd0F7/4cEe5b5MvjJ94yXKlbWt4iQfykyOzgle5j8927o63jbO2f3fzkSN3g+v0ckP4Hju5jt9wji84nYc5lecxcAf5gSM3kW+yiG95bie5bOc5kMO5kENja/O3g3e5VRP6kmM5jMb5mbf4HE+5fA/6QY859dKzmQu0okt5oDP6NNt5oZP/uYF7enmD+oTX+aNzuRSbOqd3OJ8beWxr+qWreXKLuj+3d5lneKD7OcDKeIXrOqBveAV3+q8b+6tbuZzD+H1n+izjd2lP6qR/Oprj9K4DqqPfOqS/NF9q+bLf8WcP+7Or93Sr8EXrd7GLe7CPrLZju03Du5v3Oqore5+bN3fPO32ze61rc4HveaoDe76H+Jq3ubD3OJ57u54fOq0/N8EX+aibOzAf/IPXe8Dfu79HO5KXO4BHdq4n4VOjs4Wv+EnHu6Xvu4lzu7T/+Klj/Md7eYxfeswzuL4zu5jHuv7aO8w7u/2mfEp3vMLfvNAvJZP/xlczxGJP9U5fe6XHaqt3//vQY/qm67wylkrPqTbPUzq/Z7u4SzyU//z6TmwdQhQASNRM4/jWo7v2Bv3UJ7zbL7yhG8zZm30ukoAFGFXe6/3e833f+/3fA37gC/7gE37hG/7hI37iK/7iG/5Dlj3dS5av+M3kZ31bohFRXz7mV37mP9HmU77mgz5IAiR2MsDVR10zIHDqS77ns37oG73q89Xnd77rMzns/6TlLybSy/Rv2P7ty77o437rA3/w036kyz2K9/7oKz/xF/8O5+HzM//w/37tx/70G7/Lz37zH//1yzrnv77zn9Xqa//2fzv3V730W3/5qz/Do3/2u3/7v7/5nz/4L3/0U3/1jz/2f/8//sc/CADiCAjkiaJmypJrC78wK8+qTeNtrff+D+zxhEHRUHfEJW3LWXNXNEaf0CI1F7ymtDerdxoNi8cx8DdrRp9/3K76DWy71ux0nF4n6/f2PNx/h0f0B1joIzeCKEU4yIgk2FPBN0mJI1l0GZQJtPnT6fMZiRkWqlNqGXVqowrD2poKq1k5S1tre4ubq7vL2+v7CxwsPExcbHyMnKy8zNzs/AwdLT1NXW19jZ2tvc3d7f0NHi4+Tl5urm3AILBAcAIhAC+Tvt4+ohAPr/CAb9CiwNAPx7+AJN7Fs+EAHrsfCeABDHJAAEEcBuEFMXjAxz18CnxEFMDgwY+PDer/CXwIQEEDeCJhDCTRIKONlwAeqBPQ0iXKjwJk6pxooOcMmvviTWRBE8ABdQnOkWCQ0UEDdxBSQAUglcWBBTW5zvh4VCu8sBCq6ojQLkKEIll/FA0Lo2wUCAujbPWBQIAErF51EBDQ7sBUHGBFqAUgQQCCFoUBBBX6dawIByKXRpZ4IvFixpJFEFDnM0XjB31tjMbplMTfxUHdKSS42vEQBCFrxgu9BS4Nsq97OFgbJILZHhIYJNbNwuAC5CzyMrdBO6eOBREQHACuI3G72EgCGjfyHPOIBLh3HC2u5OhdJgH/kS6vImBRyOxFxExNorXsjiggMBihX1D8kdDWCPuY/5SbEMj5p0M6A/awzwIP2hCUAfc8l9x/PgR1E3wIDeZRAwks90MEDimmIHhGSJfgeB7GR4ICC+xVnwgbYVhCPzJmtMCLiRx1YHpG3NRUarHphwKSR/JwIYzmpcgCkjCQhuBIpdlQUWcbtvGXCIlNOJN4PSy52UgadifCdzk6MRF5aHpWm5CqCQAmjPPB4+OaJ4gZg3c6xunUVVk1WRIAEBSZZlRT7TNCBIhGIJJNZbYoJ6HtHGpDAg1MqoNKHTlwpkZ82lAopj/UplmJiI6pl22c4pBOnnsGdFiqfZLgppxbVXkrAAn0o12NI/RYI6Q1MfBqi8KlpKZT8yzUpIkCFP8KoDoLMSqbSR8BigJPw3EGT1XRwkOtP/jQ2QMC0pIIRJM9SFtuDwYsABKLFAIGkUP2zoBRD96mtBJq4ApQ1WPrXEYwAPTGs+8I//KU57/D+viwvqbFI27ADuDHcccefwxyyCKPTHLJJp+Mcsoqr8xyyy6/DHPMMs9Mc80234xzzjrvzHPPPv8MdNBCD0100UYfjXTSSi/NdNNOPw111FJPTXXVVl+NddZab811116Lsc+qlcjIQJ1fnx3zR7LCQBuytyQmNtpyv7zwlSPRZ8tKvM7NN8ocqhOQBPTe1A5p8CQwYUP8mZhRUFwZLgDiWMVTW0IJNIQA5Pjatnbfnnf//E5ZCdMmUV6ABdVURGIzcGZiU71zAOpKRZ5fPgnF85fbc2L3ee8jA57Yf4lxZToBWYJEQl4gKgwY6wgc/x8B0sJDQELAbcQAZSP8xbvv3nd8J0vDA1B86C2wTkJE9FZl/lM9FW/9CBKAypJnAnT/ff7nNGTWO4iDpIC/ACZ47ZBA9xRnD9whBiQFrM5YHlO9+6GAXi3ZR+f0h8Fs3EgEj9GHOgLWkQcEDG+zC42JECXC28xuWtSL3wJVaJ/NZXCGH4sQDtpWJnrRiA9wo6EP8TO9BOwtBWHz0sEmQTaz/XCJTGyiE58IxShKcYpUrKIVr4jFLGpxi1zsohe/CMYwGIpxjGQsoxnPiMY0qnGNbGyjG98IR2eEAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mean sleep time of 493 healthy Swiss children enrolled in the Zurich Longitudinal Studies, based on parent report. Error bars represent &plusmn;2 standard deviations (which includes 97 percent of the population). The&nbsp;dashed red line represents the lower limit of sleep time for each age group, as recommended by the Centers for Disease Control and Prevention (CDC).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Iglowstein I, Jenni OG, Molinari L, Largo RH. Sleep duration from infancy to adolescence: Reference values and generational trends. Pediatrics 2003; 111:302.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_0_14351=[""].join("\n");
var outline_f14_0_14351=null;
